[
  {
    "id": "rag_asthma_diagnosis_2e70abde",
    "question": "A 45-year-old male with newly diagnosed smear-positive pulmonary tuberculosis, who also has Type 2 Diabetes Mellitus, is initiated on a standard four-drug antitubercular regimen including isoniazid. What is the most appropriate initial management step to prevent a common neurological adverse effect of isoniazid in this patient?",
    "options": {
      "A": "Prescribe pyridoxine 25-50 mg daily concurrently with isoniazid.",
      "B": "Instruct the patient to report any neurological symptoms for subsequent pyridoxine initiation.",
      "C": "Initiate pyridoxine 100 mg daily to ensure maximal protection against neuropathy.",
      "D": "Advise that peripheral neuropathy is a rare and self-limiting side effect in diabetic patients."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Isoniazid (INH) causes a functional pyridoxine (vitamin B6) deficiency, leading to peripheral neuropathy. Patients with diabetes are identified as a high-risk group for INH-induced neuropathy. Pyridoxine supplementation (25-50 mg daily) is recommended for all high-risk individuals, including those with diabetes, HIV, renal disease, and alcohol abuse, to prevent this adverse effect. Prophylactic administration is standard practice in these patient populations.",
    "highYieldPearl": "Rio's Take: Pyridoxine prophylaxis with INH is crucial for high-risk patients. Remember the common risk factors: diabetes, HIV, renal failure, alcohol abuse, malnutrition, pregnancy, and advanced age.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Correct. Diabetes is a high-risk factor for INH neurotoxicity, necessitating prophylactic pyridoxine 25-50mg daily to prevent neuropathy.",
      "B": "Trap. This approach is reactive and not recommended for high-risk patients, who require prophylactic supplementation. Delaying treatment until symptoms appear increases the risk of developing significant and potentially irreversible neuropathy.",
      "C": "Trap. A dose of 100 mg daily is typically reserved for treating *existing* neuropathy, not for initial prophylaxis. Starting with a higher dose without a clinical indication is not the standard recommendation.",
      "D": "Trap. Peripheral neuropathy is a significant and potentially debilitating side effect of INH, especially in high-risk groups like diabetics. It is not always rare or self-limiting, and intervention (pyridoxine) is often required."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_586ca192",
    "question": "A 38-year-old male with HIV infection, on efavirenz-based antiretroviral therapy for two years, is diagnosed with pulmonary tuberculosis and started on standard antitubercular treatment, including isoniazid. Three weeks later, he presents to the emergency department with acute onset confusion, rapid breathing, and severe metabolic acidosis (pH 7.18, HCO3 9 mEq/L, PCO2 22 mmHg) with an elevated anion gap of 26 mEq/L. His random blood glucose is 105 mg/dL, and serum creatinine is 0.9 mg/dL. He denies alcohol intake or other recent drug exposures. Which of the following is the most likely cause of his current metabolic derangement?",
    "options": {
      "A": "Isoniazid-induced lactic acidosis.",
      "B": "Diabetic ketoacidosis.",
      "C": "Zidovudine-induced lactic acidosis.",
      "D": "Uremic acidosis."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient presents with high anion gap metabolic acidosis (HAGMA). Given his recent initiation on isoniazid (INH) for TB treatment and the absence of other clear causes, INH toxicity leading to Type B lactic acidosis is the most likely diagnosis. The provided context explicitly lists isoniazid toxicity as a cause of Type B lactic acidosis without hypoxia. Diabetic ketoacidosis is ruled out by the normal blood glucose. While zidovudine (AZT) can cause lactic acidosis, the vignette specifies an efavirenz-based regimen, making AZT toxicity less likely unless he was on it prior, which is not mentioned. Uremic acidosis is ruled out by the normal serum creatinine.",
    "highYieldPearl": "Rio's Take: Always consider drug-induced metabolic derangements in patients on multiple medications, especially antituberculars and antiretrovirals. Isoniazid toxicity is a classic cause of Type B lactic acidosis.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Correct. Isoniazid toxicity is a known cause of high anion gap metabolic acidosis, specifically Type B lactic acidosis, which fits the clinical picture and laboratory findings perfectly.",
      "B": "Trap. Diabetic ketoacidosis is ruled out by the patient's normal blood glucose level (105 mg/dL) and lack of diabetes history.",
      "C": "Trap. While zidovudine (AZT) is a known cause of lactic acidosis in HIV patients, the vignette states the patient is on an 'efavirenz-based antiretroviral therapy.' Without specific mention of zidovudine use, INH toxicity is a more direct and current likely cause given the recent ATT initiation.",
      "D": "Trap. Uremic acidosis (a form of high anion gap metabolic acidosis) is ruled out by the normal serum creatinine level (0.9 mg/dL), indicating normal renal function."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b0c91bdf",
    "question": "A 30-year-old male with chronic HIV infection, with a CD4 count of 180 cells/µL, presents with progressive dyspnea, chronic dry cough, and recurrent episodes of mild fever over the past 6 months. A recent chest CT scan reveals multiple bilateral thin-walled cysts of variable size, uniformly distributed throughout all lung fields, some exhibiting internal septations. Evaluation for active tuberculosis and other opportunistic infections was negative. Based on the clinical context and imaging findings, what is the most likely underlying pulmonary condition?",
    "options": {
      "A": "Lymphoid Interstitial Pneumonia (LIP).",
      "B": "Lymphangioleiomyomatosis (LAM).",
      "C": "Pulmonary Langerhans Cell Histiocytosis (PLCH).",
      "D": "Birt-Hogg-Dubé syndrome (BHD)."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient's history of chronic HIV infection, along with a low CD4 count, and the characteristic CT findings of multiple bilateral thin-walled cysts of variable size, uniformly distributed, some with internal septations, strongly point towards Lymphoid Interstitial Pneumonia (LIP). The provided context explicitly lists LIP/FB (Lymphoid Interstitial Pneumonia / Follicular Bronchiolitis) as being associated with HIV and describes its CT features as cysts of variable size, distributed uniformly across all lung fields with slight lower-lobe predominance, often with internal septations. Active TB and other opportunistic infections have been ruled out, further supporting this diagnosis.",
    "highYieldPearl": "Rio's Take: In an HIV patient with cystic lung disease, Lymphoid Interstitial Pneumonia (LIP) is a primary consideration, especially with characteristic diffuse cysts and lower CD4 count. Always prioritize ruling out opportunistic infections in this population first.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Correct. LIP is highly associated with HIV infection, particularly with lower CD4 counts, and its CT features (variable sized, uniformly distributed cysts, often with septations) perfectly match the description in the vignette and the provided context.",
      "B": "Trap. LAM is predominantly a disease of women (strong female predilection) and is associated with renal angiomyolipomas and Tuberous Sclerosis Complex, not primarily with HIV. While LAM also presents with diffuse cysts, the patient's demographics make LIP a far more likely diagnosis.",
      "C": "Trap. PLCH is strongly associated with smoking, typically affects the upper lobes with characteristic costophrenic angle sparing, and cysts often have bizarre shapes and can be accompanied by nodules or cavities. These features do not align as well with the vignette's description.",
      "D": "Trap. BHD is an autosomal dominant genetic syndrome associated with skin lesions and renal tumors, with characteristic basal/subpleural or perivascular cysts. It has no primary association with HIV, making it an unlikely diagnosis in this context."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_a25762bb",
    "question": "A 55-year-old male with Type 2 Diabetes Mellitus is diagnosed with pulmonary tuberculosis and started on standard anti-tuberculous therapy including Isoniazid. To prevent a common neurological side effect, what supplementation should be prescribed?",
    "options": {
      "A": "Pyridoxine (Vitamin B6)",
      "B": "Thiamine (Vitamin B1)",
      "C": "Folic Acid (Vitamin B9)",
      "D": "Cyanocobalamin (Vitamin B12)"
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Isoniazid (INH) causes a functional deficiency of pyridoxine (vitamin B6). This deficiency is particularly clinically significant in high-risk patients, including those with diabetes, HIV, renal disease, alcohol abuse, malnutrition, or advanced age, leading to peripheral neuropathy. Therefore, pyridoxine supplementation (typically 25-50 mg with each INH dose) is routinely recommended for these patients to prevent this adverse effect.",
    "highYieldPearl": "Rio's Take: Pyridoxine prophylaxis is crucial with INH in high-risk patients like diabetics, HIV, or renal failure to prevent neuropathy.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Correct. Pyridoxine directly counteracts INH-induced functional Vitamin B6 deficiency, which is the cause of peripheral neuropathy.",
      "B": "Thiamine is essential for carbohydrate metabolism and nerve function but is not specifically indicated for INH-induced neuropathy.",
      "C": "Folic acid is important for cell division and DNA synthesis; its deficiency causes megaloblastic anemia but is not related to INH neurotoxicity.",
      "D": "Cyanocobalamin is crucial for nerve tissue health and red blood cell formation, and its deficiency can also cause neuropathy, but it is not the specific supplement required to prevent INH-induced neuropathy."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_21e1fdca",
    "question": "A 30-year-old male, recently started on antitubercular therapy including Isoniazid for pulmonary tuberculosis, presents to the emergency department with generalized tonic-clonic seizures. His labs reveal no other obvious metabolic derangements. What is the most appropriate immediate pharmacological intervention for suspected Isoniazid-induced seizures?",
    "options": {
      "A": "Intravenous Pyridoxine",
      "B": "Intravenous Lorazepam",
      "C": "Intravenous Phenytoin",
      "D": "Oral Pyridoxine"
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Isoniazid (INH) toxicity, particularly in overdose situations, can lead to severe neurotoxicity including seizures and status epilepticus. INH interferes with pyridoxine (vitamin B6) metabolism, specifically by inhibiting pyridoxine phosphokinase, an enzyme essential for converting pyridoxine to its active form, pyridoxal-5-phosphate. This active form is a co-factor for glutamic acid decarboxylase, which produces GABA (an inhibitory neurotransmitter). Decreased GABA levels lead to neuronal hyperexcitability and seizures. Immediate treatment involves intravenous pyridoxine, which directly replenishes the deficient vitamin B6, along with antiepileptic drugs if necessary.",
    "highYieldPearl": "Rio's Take: Acute INH toxicity causing seizures is an emergency; IV pyridoxine is the specific antidote.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Correct. Intravenous pyridoxine is the specific antidote for INH-induced seizures as it directly reverses the underlying mechanism of toxicity.",
      "B": "Intravenous lorazepam is a benzodiazepine used to terminate acute seizures. While it may be used as an adjunct to control seizures, it does not address the underlying INH toxicity.",
      "C": "Intravenous phenytoin is an antiepileptic drug that can be used for seizure control, but like lorazepam, it does not directly treat the specific INH toxicity. It's often used for status epilepticus.",
      "D": "Oral pyridoxine is used for prophylaxis or treatment of mild peripheral neuropathy. For acute, life-threatening events like seizures, intravenous administration is crucial for rapid action and higher bioavailability."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_374c6332",
    "question": "A 40-year-old male with a known history of HIV infection presents with chronic cough and dyspnea. A CT chest scan reveals multiple thin-walled cysts of variable size, uniformly distributed across all lung fields, with some cysts showing internal septations. Based on the clinical vignette and CT findings, which of the following cystic lung diseases is most strongly associated with HIV infection?",
    "options": {
      "A": "Lymphangioleiomyomatosis (LAM)",
      "B": "Birt-Hogg-Dubé (BHD) syndrome",
      "C": "Pulmonary Langerhans Cell Histiocytosis (PLCH)",
      "D": "Lymphoid Interstitial Pneumonia / Follicular Bronchiolitis (LIP/FB)"
    },
    "correctAnswer": "D",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Lymphoid Interstitial Pneumonia (LIP) and Follicular Bronchiolitis (FB) are strongly associated with underlying systemic conditions, particularly autoimmune diseases (like Sjögren's Syndrome) and immunodeficiency states such as HIV infection. The CT findings described—cysts of variable size, uniformly distributed, often with internal septations—are consistent with LIP/FB. Other cystic lung diseases like LAM, BHD, and PLCH have distinct associations and typical CT patterns that do not primarily point to HIV infection.",
    "highYieldPearl": "Rio's Take: LIP/FB is the cystic lung disease most commonly linked to HIV, presenting with diffuse cysts, sometimes with septations.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "LAM is typically seen in women and associated with Tuberous Sclerosis Complex (TSC) and renal angiomyolipomas. It is not primarily associated with HIV.",
      "B": "BHD syndrome is an autosomal dominant disorder associated with renal tumors, skin fibrofolliculomas, and FLCN gene mutations. While it causes cysts, it lacks a direct association with HIV.",
      "C": "PLCH is strongly associated with smoking, and typically presents with nodules, thick-walled cavities, and bizarre-shaped cysts predominantly in the upper lobes with costophrenic angle sparing. HIV is not a primary association.",
      "D": "Correct. The provided text explicitly lists HIV as an extrapulmonary manifestation/association for LIP/FB, and the CT findings described are consistent with this diagnosis."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_696f8ba4",
    "question": "A 55-year-old male with long-standing type 2 diabetes and recently diagnosed HIV-associated pulmonary tuberculosis initiated a standard RIPE regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol). Due to his comorbidities, he was prescribed pyridoxine 50 mg daily alongside isoniazid. Three weeks later, he complains of a burning sensation and numbness in his feet, particularly at night. Physical examination confirms mild distal sensory neuropathy. What is the most appropriate next step in his management?",
    "options": {
      "A": "Increase oral pyridoxine to 100 mg daily.",
      "B": "Discontinue isoniazid and replace it with levofloxacin.",
      "C": "Administer intravenous pyridoxine immediately.",
      "D": "Reassure the patient that symptoms typically resolve with continued TB medication and offer symptomatic relief."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient presents with symptoms of peripheral neuropathy, a well-known neurotoxic adverse effect of isoniazid (INH), especially in high-risk individuals such as those with diabetes and HIV, as described in the provided text. Pyridoxine (vitamin B6) deficiency is the underlying mechanism. The text states that pyridoxine (25-50 mg) is given with each INH dose to high-risk patients for prophylaxis. Crucially, it also specifies: 'For patients who develop neuropathy while on pyridoxine, doses may be increased to 100 mg daily.' Since the patient was already on prophylactic pyridoxine (50 mg daily) and developed neuropathy, increasing the dose to 100 mg daily is the most appropriate next step to manage and mitigate INH-induced neuropathy.",
    "highYieldPearl": "Rio's Take: INH-induced neuropathy is dose-dependent and preventable/treatable with pyridoxine. While prophylaxis is 25-50mg daily, established neuropathy, even on prophylaxis, warrants an increase to 100mg daily. Differentiating this from other neurotoxic effects is key.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is the correct management based on the provided text, specifically addressing the development of neuropathy despite prophylactic pyridoxine.",
      "B": "Discontinuing INH is a drastic measure and typically reserved for severe, life-threatening adverse effects or confirmed INH resistance. Peripheral neuropathy, while significant, is usually manageable with pyridoxine dose adjustment, allowing continuation of the crucial INH therapy. Levofloxacin is not a standard first-line replacement for INH without clear indications like drug resistance.",
      "C": "Intravenous pyridoxine is indicated for acute, severe INH toxicity, particularly in cases of seizures or overdose, which is not the scenario described here (mild distal sensory neuropathy).",
      "D": "The text mentions that 'Other neurotoxic adverse effects typically resolve with continuation of TB medications and are best addressed with supportive methods.' This option is a plausible trap, as it correctly states that *some* neurotoxic effects may resolve. However, INH-induced peripheral neuropathy, specifically linked to pyridoxine deficiency, has a direct and specific management strategy (increasing pyridoxine) outlined in the text, distinguishing it from general 'other neurotoxic adverse effects' that might spontaneously resolve."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_71447a85",
    "question": "A 38-year-old male with HIV infection, currently on antiretroviral therapy with a CD4 count of 350 cells/µL, presents with progressive dyspnea and dry cough over several months. Chest CT scan reveals diffuse, thin-walled cysts of variable size, uniformly distributed throughout all lung fields, some with internal septations. Bronchoscopy with transbronchial biopsy is performed. What is the most likely diagnosis given the clinical and radiological findings, and what characteristic finding would be expected on histology?",
    "options": {
      "A": "Lymphangioleiomyomatosis (LAM); Infiltration by HMB-45-positive LAM cells.",
      "B": "Birt-Hogg-Dubé syndrome (BHD); Cysts abutting interlobular septa lacking abnormal cell proliferations.",
      "C": "Lymphoid Interstitial Pneumonia (LIP); Diffuse interstitial polyclonal lymphocytic infiltrate.",
      "D": "Pulmonary Langerhans Cell Histiocytosis (PLCH); S100 and CD1a-positive Langerhans cells with Birbeck granules."
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient's history of HIV infection and the CT findings of diffuse, thin-walled cysts of variable size, uniformly distributed across all lung fields, with some internal septations, are highly characteristic of Lymphoid Interstitial Pneumonia (LIP). The provided text explicitly lists HIV as a major association for LIP/Follicular Bronchiolitis. The histological description of LIP, as noted in the table, is 'Diffuse interstitial polyclonal lymphocytic infiltrate.' This combination perfectly matches the scenario.\n\nLet's analyze why other options are less likely:\n- LAM (A) is predominantly a disease of women (women >> men) and while it presents with cysts, the patient's sex makes it less likely without other clear signs of TSC. Histology is correct for LAM.\n- BHD (B) typically presents with cysts predominantly located in basilar, subpleural areas or abutting vasculature, which differs from the described uniform distribution. Histology is correct for BHD but less likely given the overall picture.\n- PLCH (D) is strongly associated with smoking, and its CT findings typically include both nodules and bizarrely shaped cysts, more prominent in the upper lobes with costophrenic angle sparing. This does not align with the described diffuse, uniform, variable-sized cysts. Histology is correct for PLCH.",
    "highYieldPearl": "Rio's Take: HIV-associated cystic lung disease often points to LIP. Key differentiating features for cystic lung diseases involve sex predilection, specific CT patterns (distribution, shape, associated nodules), and relevant extrapulmonary manifestations or associations.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "LAM presents with diffuse cysts and has a correct histological marker (HMB-45), making it a plausible but incorrect option. However, the strong female predilection (women >> men) and the lack of other TSC features make it less likely in this male patient with HIV, even though 'uniform distribution' is mentioned for both LAM and LIP.",
      "B": "BHD is another cause of cystic lung disease with a correct histological description. However, the CT pattern ('Round-lentiform thin-walled cysts, predominantly located in the basilar, subpleural areas or abutting the pulmonary vasculature') differs from the diffuse, uniform distribution described in the vignette.",
      "C": "This is the correct answer. LIP is explicitly associated with HIV in the text. The CT findings (cysts of variable size, distributed uniformly across all lung fields, often with internal septations) precisely match the vignette. The histological finding (diffuse interstitial polyclonal lymphocytic infiltrate) is also accurate for LIP.",
      "D": "PLCH can cause cysts and has correct histological markers (S100, CD1a). However, it is strongly associated with smoking and typically shows a different CT pattern (nodules, bizarre cysts, upper lobe predominance with costophrenic sparing) than described, making it less likely in this context."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_7891d1dd",
    "question": "A 60-year-old male with a history of chronic kidney disease (CKD stage 4, baseline creatinine 3.0 mg/dL) and well-controlled type 2 diabetes mellitus presents to the emergency department with altered mental status and rapid breathing. He was recently diagnosed with pulmonary tuberculosis and has been on a standard RIPE regimen including isoniazid for the past month. Arterial blood gas analysis reveals a pH of 7.20, PaCO2 25 mmHg, HCO3 10 mEq/L, and an anion gap of 22 mEq/L. Serum lactate is mildly elevated at 3.5 mmol/L (normal < 2.0 mmol/L). His blood glucose is 180 mg/dL. Urine ketones are negative. Creatinine is 4.5 mg/dL. What is the most likely combination of factors contributing to his anion gap metabolic acidosis?",
    "options": {
      "A": "Diabetic ketoacidosis and uremia.",
      "B": "Uremia and isoniazid-induced Type B lactic acidosis.",
      "C": "Salicylate toxicity and Type A lactic acidosis.",
      "D": "Methanol poisoning and starvation ketoacidosis."
    },
    "correctAnswer": "B",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient presents with a high anion gap metabolic acidosis (pH 7.20, HCO3 10 mEq/L, AG 22 mEq/L). We need to identify the most likely causes based on his medical history, medications, and laboratory findings, referencing the provided text:\n\n1.  **High Anion Gap Acidosis (AG 22):** This indicates an accumulation of unmeasured anions.\n2.  **Blood Glucose 180 mg/dL, Urine Ketones Negative:** These findings effectively rule out diabetic ketoacidosis (DKA), which typically presents with much higher glucose levels and significant ketonuria.\n3.  **Creatinine 4.5 mg/dL:** This signifies worsening renal failure (from baseline 3.0 mg/dL). 'Uremia' is explicitly listed as a cause of anion gap acidosis in the provided text.\n4.  **Serum Lactate 3.5 mmol/L (mildly elevated):** This indicates a component of lactic acidosis. The text lists 'Isoniazid toxicity' and 'Renal failure' as causes of Type B lactic acidosis (altered lactate metabolism without hypoxia). Since the patient is on isoniazid and has renal failure, both can contribute to this mild lactate elevation.\n5.  **No history of ingestion of salicylates or methanol, and no signs of starvation.** This rules out options C and D.\n\nTherefore, the most likely combination of factors contributing to his acidosis is uremia (due to CKD) and Type B lactic acidosis, which is directly attributable to both his renal failure and isoniazid therapy.",
    "highYieldPearl": "Rio's Take: When facing high anion gap metabolic acidosis in complex patients, systematically rule out the 'MUDPILES' causes. Always consider drug-induced etiologies, especially when specific medications like INH are mentioned alongside comorbidities like renal failure and diabetes that independently predispose to different forms of acidosis.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "Diabetic ketoacidosis is a plausible cause of acidosis in a diabetic patient, making this a strong trap. However, the blood glucose level (180 mg/dL) is not high enough to suggest DKA, and the negative urine ketones effectively rule it out. Uremia is a correct factor, but DKA is not.",
      "B": "This is the correct answer. Uremia is indicated by the elevated creatinine and CKD history. Isoniazid is explicitly listed in the text as a drug causing Type B lactic acidosis, and renal failure itself can contribute to altered lactate metabolism. The mildly elevated lactate supports this component.",
      "C": "Salicylate toxicity is a cause of AGA, but there is no information in the vignette to suggest salicylate ingestion. Type A lactic acidosis (due to tissue hypoxia) is not strongly supported as the primary cause, as the lactate is only mildly elevated, and no clear signs of shock or severe hypoxemia are provided.",
      "D": "Methanol poisoning and starvation ketoacidosis are both causes of AGA, but there is no clinical or laboratory evidence to support either in this patient. Urine ketones being negative rules out starvation ketoacidosis."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b0404525",
    "question": "A 65-year-old male with type 2 diabetes mellitus and stage 4 chronic kidney disease is initiated on isoniazid (INH) as part of his antituberculosis regimen. Despite receiving pyridoxine 50 mg daily, he develops numbness and tingling in his feet after 3 months. Which of the following is the most appropriate next step in managing his peripheral neuropathy?",
    "options": {
      "A": "Increase pyridoxine to 100 mg daily.",
      "B": "Discontinue isoniazid immediately.",
      "C": "Switch isoniazid to ethambutol.",
      "D": "Administer intravenous pyridoxine."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient has multiple risk factors for INH-induced peripheral neuropathy, including type 2 diabetes mellitus and chronic renal disease. The provided text states that pyridoxine (25-50 mg) is given with each INH dose to all persons at risk. It further specifies, 'For patients who develop neuropathy while on pyridoxine, doses may be increased to 100 mg daily; supplementation above this dose is unlikely to be helpful.' Therefore, increasing the pyridoxine dose to 100 mg daily is the next appropriate step to manage his developing neuropathy while continuing INH.",
    "highYieldPearl": "Rio's Take: Pyridoxine prophylaxis is crucial for INH, especially in high-risk groups (diabetes, HIV, renal failure, malnutrition, alcohol abuse, pregnancy, advanced age). If neuropathy develops despite prophylaxis, increasing pyridoxine to 100 mg daily is the first line, before considering INH discontinuation.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is the correct management as per the provided text for developing neuropathy despite standard pyridoxine prophylaxis.",
      "B": "Discontinuing isoniazid is a drastic measure and typically not the initial step for managing peripheral neuropathy unless it is severe, rapidly progressive, or refractory to increased pyridoxine. The goal is to complete TB treatment if possible.",
      "C": "Switching isoniazid to another drug like ethambutol would alter the TB regimen significantly and is not the primary intervention for INH-induced neuropathy. Ethambutol has its own side effects, including optic neuritis.",
      "D": "Intravenous pyridoxine is indicated for acute severe INH toxicity, such as seizures or overdose, not for gradual onset peripheral neuropathy under therapeutic dosing."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_ae2ebbd6",
    "question": "A 40-year-old male with HIV presents with progressive dyspnea and cough. A CT scan of the chest reveals multiple thin-walled cysts distributed uniformly across all lung fields, with some cysts showing internal septations and associated ground-glass attenuation in the adjacent parenchyma. Considering the patient's HIV status, which of the following characteristics would be LEAST suggestive of Lymphoid Interstitial Pneumonia (LIP)?",
    "options": {
      "A": "A slight predominance of cysts in the lower lobes.",
      "B": "Associated findings of renal angiomyolipomas.",
      "C": "Evidence of peribronchiolar follicular lymphoid hyperplasia on lung biopsy.",
      "D": "Presence of diffuse interstitial polyclonal lymphocytic infiltrate on lung biopsy."
    },
    "correctAnswer": "B",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient's HIV status and CT findings (thin-walled cysts uniformly distributed, with septations and ground-glass) are highly consistent with Lymphoid Interstitial Pneumonia (LIP). The question asks for the characteristic LEAST suggestive of LIP.\n\n- Option A: The table states for LIP/FB, 'Cysts of variable size, distributed uniformly across all lung fields with slight lower‑lobe predominance.' Therefore, a slight lower lobe predominance is consistent with LIP.\n- Option B: Renal angiomyolipomas are listed as extrapulmonary manifestations of Lymphangioleiomyomatosis (LAM), a distinct cystic lung disease, often associated with Tuberous Sclerosis Complex (TSC). They are not characteristic of LIP.\n- Option C: Peribronchiolar follicular lymphoid hyperplasia with germinal centers is characteristic of Follicular Bronchiolitis (FB), which is often considered part of the LIP/FB spectrum or a related lymphocytic interstitial lung disease. This is consistent with the general category.\n- Option D: A diffuse interstitial polyclonal lymphocytic infiltrate is the defining pathological finding of LIP itself, as per the table. This is highly suggestive of LIP.\n\nThus, associated renal angiomyolipomas would be the finding LEAST suggestive of LIP.",
    "highYieldPearl": "Rio's Take: LIP/FB is strongly associated with HIV, presenting with diffuse cysts, sometimes with lower lobe predominance, and can have associated ground-glass. Differentiating cystic lung diseases requires meticulous attention to associated extrapulmonary manifestations and specific CT/pathologic features. Renal angiomyolipomas are a classic LAM finding, not LIP.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is a plausible finding for LIP, as the context mentions 'slight lower‑lobe predominance' for LIP cysts.",
      "B": "This is the correct answer. Renal angiomyolipomas are characteristic of LAM and TSC, not LIP. This is a clear differentiating factor.",
      "C": "Peribronchiolar follicular lymphoid hyperplasia is characteristic of Follicular Bronchiolitis (FB), which is often grouped with or considered part of the spectrum of LIP/FB, especially in the context of HIV. Thus, it is a suggestive finding.",
      "D": "Diffuse interstitial polyclonal lymphocytic infiltrate is the hallmark pathological finding for LIP, making this a highly suggestive characteristic."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_891a4002",
    "question": "A 55-year-old male with a history of poorly controlled type 2 diabetes mellitus and stage 3 chronic kidney disease develops altered mental status, Kussmaul respirations, and severe metabolic acidosis (pH 7.18, HCO3 8 mEq/L, anion gap 28 mEq/L) three hours after accidentally taking a double dose of his isoniazid (INH) medication (total 1200 mg). In this patient, which of the following findings would most strongly support INH toxicity as the primary cause of the acidosis, over diabetic ketoacidosis or uremia?",
    "options": {
      "A": "Elevated serum creatinine and BUN.",
      "B": "Presence of large ketones in urine.",
      "C": "Development of new-onset generalized tonic-clonic seizures.",
      "D": "A serum lactate level of 2.8 mmol/L (reference < 2.2 mmol/L)."
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "This patient presents with a severe high anion gap metabolic acidosis, and has risk factors for Diabetic Ketoacidosis (DKA) due to poorly controlled diabetes and Uremia due to chronic kidney disease (CKD). He also had an acute INH overdose.\n\n- Option A: Elevated serum creatinine and BUN would be expected given his stage 3 CKD and would be consistent with uremic acidosis. However, uremic acidosis typically has a milder anion gap (15-20 mEq/L) and is not usually as acutely severe (pH 7.18, AG 28) or sudden-onset as seen here, following an overdose. Thus, while present, it wouldn't be the *most strongly* supportive for the *acute, severe* acidosis caused by the overdose.\n- Option B: Presence of large ketones in urine would strongly suggest DKA as the primary cause of the acidosis. If present, it would point away from INH as the *sole* primary cause of acidosis.\n- Option C: The provided text explicitly states, 'Seizures, including status epilepticus, may develop as a result of INH toxicity (including overdoses).' The sudden onset of generalized tonic-clonic seizures shortly after an INH overdose is a highly specific and severe neurotoxic manifestation of INH poisoning. This severe acute presentation strongly indicates significant INH toxicity, which *in turn* causes profound metabolic derangements, including severe lactic acidosis, leading to the high anion gap acidosis. While DKA can cause altered mental status, acute tonic-clonic seizures are not a primary, direct, and common feature of DKA itself, and are far less typical for uremic encephalopathy in this acute manner.\n- Option D: Isoniazid toxicity is listed as a cause of Type B lactic acidosis. While a lactate level of 2.8 mmol/L is mildly elevated, it is not particularly high (severe lactic acidosis is typically >4-5 mmol/L). An anion gap of 28 mEq/L suggests a substantial contribution from unmeasured anions. If lactate were the primary cause of such a high anion gap, the lactate level would typically be much higher. Therefore, this mild elevation in lactate does not *most strongly* explain the severe acidosis compared to the highly specific neurotoxic effect (seizures) of INH overdose.",
    "highYieldPearl": "Rio's Take: INH overdose is characterized by acute, severe neurotoxicity (seizures) and metabolic derangements, including high anion gap lactic acidosis. In a context of competing causes (DKA, uremia), the development of seizures after an acute INH overdose is a powerful diagnostic clue pointing to severe INH toxicity as the primary driving factor for the entire clinical picture, including the severe acidosis.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is a plausible finding due to CKD, but less specific for the *acute, severe* acidosis from INH overdose compared to the other options. Uremic acidosis itself is typically milder.",
      "B": "This would point more towards DKA as the primary cause, not INH toxicity.",
      "C": "This is the most compelling answer. Seizures are a direct, acute, and severe neurotoxic manifestation of INH overdose, as explicitly stated in the text. Such severe acute toxicity is the underlying reason for the profound metabolic derangement, including the acidosis.",
      "D": "While INH causes lactic acidosis, a lactate of 2.8 mmol/L is only mildly elevated and would not fully account for an anion gap of 28 mEq/L. This makes it less convincing as the *most strongly* supportive finding for the *primary cause* of the severe acidosis, especially when compared to the highly specific and severe manifestation of seizures from INH overdose."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_170ea189",
    "question": "A 45-year-old male with newly diagnosed pulmonary TB, HIV (on ART, CD4 300), Type 2 Diabetes Mellitus (on metformin), and Stage 3 chronic kidney disease presents with worsening generalized weakness, paresthesias in his extremities, and confusion 2 months after initiating antitubercular treatment (ATT) including Isoniazid. Lab investigations reveal severe metabolic acidosis with an elevated anion gap. His latest random blood glucose is 180 mg/dL.",
    "options": {
      "A": "Administer intravenous pyridoxine, hold metformin, and provide intravenous fluids.",
      "B": "Discontinue Isoniazid, increase oral pyridoxine to 100 mg daily, and administer intravenous sodium bicarbonate.",
      "C": "Increase oral pyridoxine to 50 mg daily, continue Isoniazid, and initiate hemodialysis.",
      "D": "Discontinue all ATT, start broad-spectrum antibiotics, and administer intravenous glucose."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "This patient presents with a complex scenario involving multiple risk factors for adverse drug reactions and metabolic derangements. The neurological symptoms (generalized weakness, paresthesias, confusion) in a patient on Isoniazid (INH) with diabetes, HIV, and renal disease are highly suggestive of INH-induced neurotoxicity. Since the symptoms include confusion, this indicates a significant CNS manifestation, requiring immediate intervention with intravenous pyridoxine (as per the context, for seizures/overdose, but implies for severe neurotoxicity beyond peripheral neuropathy). The severe metabolic acidosis with an elevated anion gap, in a patient on metformin with renal failure and diabetes, points to lactic acidosis. Metformin is a known cause of Type B lactic acidosis, especially in patients with renal impairment. HIV, renal failure, and INH itself can also contribute to lactic acidosis. Therefore, holding metformin and providing intravenous fluids (to improve renal perfusion and lactate clearance) are appropriate steps to address the acidosis. Intravenous pyridoxine, holding metformin, and intravenous fluids simultaneously address the most pressing neurological and metabolic issues.",
    "highYieldPearl": "Rio's Take: Severe INH neurotoxicity, particularly with CNS involvement, mandates immediate IV pyridoxine. Metformin-associated lactic acidosis requires discontinuation of the drug and supportive measures like IV fluids. In complex patients, always consider multiple contributing factors to acidosis.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This option provides the most appropriate and immediate interventions: IV pyridoxine for acute INH neurotoxicity, holding metformin for metformin-induced lactic acidosis, and IV fluids for general support and addressing acidosis.",
      "B": "While discontinuing INH may be necessary for severe toxicity, increasing oral pyridoxine to 100 mg daily is for established neuropathy, not for acute, severe CNS symptoms like confusion, which require immediate IV pyridoxine. Sodium bicarbonate may be considered for severe acidosis but is not the primary intervention for the drug-induced causes.",
      "C": "Increasing oral pyridoxine to 50 mg daily is a prophylactic dose, insufficient for established severe neuropathy. Continuing INH is inappropriate given the severe neurotoxicity. While hemodialysis might be considered for severe lactic acidosis (e.g., Metformin-Associated Lactic Acidosis with significant renal impairment), holding metformin and IV fluids are more immediate initial steps, and IV pyridoxine is essential for the neurological component.",
      "D": "Discontinuing all ATT is generally not the first step without more specific indications, as TB treatment interruption can lead to resistance. Broad-spectrum antibiotics are not indicated without evidence of infection. Administering intravenous glucose is inappropriate given the random blood glucose of 180 mg/dL and no indication of hypoglycemia or severe DKA (which typically has much higher glucose levels)."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_3504cf9e",
    "question": "A 38-year-old male with HIV on stable ART presents with recurrent pneumothorax and progressive dyspnea. CT chest reveals multiple thin-walled, uniformly distributed cysts across all lung fields, with some cysts showing internal septations. Bronchoscopy with BAL and transbronchial biopsy yielded non-diagnostic results. Serum VEGF-D levels are within normal limits.",
    "options": {
      "A": "Pulmonary Langerhans Cell Histiocytosis (PLCH)",
      "B": "Lymphangioleiomyomatosis (LAM)",
      "C": "Lymphoid Interstitial Pneumonia (LIP)",
      "D": "Birt-Hogg-Dubé syndrome (BHD)"
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient's history of HIV, recurrent pneumothorax, and specific CT chest findings are key to the diagnosis. The CT description of 'multiple thin-walled, uniformly distributed cysts across all lung fields, with some cysts showing internal septations' strongly points towards Lymphoid Interstitial Pneumonia (LIP) or Follicular Bronchiolitis (FB). The context explicitly states LIP/FB is associated with HIV and features 'cysts of variable size, distributed uniformly across all lung fields with slight lower‑lobe predominance; cysts often have internal septations or eccentric vessels'. The non-diagnostic bronchoscopy is also consistent with the low diagnostic yield mentioned for cystic lung diseases. Normal serum VEGF-D levels effectively rule out Lymphangioleiomyomatosis (LAM), where VEGF-D is typically elevated. PLCH usually presents with bizarre-shaped cysts, thick-walled cavities/nodules, and upper lobe predominance with costophrenic angle sparing, often in smokers. BHD typically features round-lentiform cysts predominantly located in the basilar, subpleural areas. Therefore, LIP is the most fitting diagnosis.",
    "highYieldPearl": "Rio's Take: Always integrate clinical context (like HIV) with specific imaging findings. 'Uniformly distributed cysts with internal septations' + HIV is a classic signature for LIP, especially when key markers for other diseases (like VEGF-D for LAM) are negative.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "PLCH typically presents with bizarre-shaped cysts, often thick-walled, and predominantly in the upper lobes with costophrenic sparing. These features do not match the 'uniformly distributed, thin-walled cysts with internal septations' described.",
      "B": "LAM features round, thin-walled cysts distributed uniformly. However, the patient's serum VEGF-D is normal, which makes LAM highly unlikely as elevated VEGF-D is a characteristic finding in LAM.",
      "C": "LIP is strongly associated with HIV. The CT findings of 'cysts of variable size, distributed uniformly across all lung fields with slight lower‑lobe predominance; cysts often have internal septations or eccentric vessels' perfectly align with the patient's description. Recurrent pneumothorax can also occur.",
      "D": "BHD typically presents with round-lentiform, thin-walled cysts predominantly located in the basilar, subpleural areas. This distribution differs from the 'uniformly distributed' cysts described in the patient."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b1a9d861",
    "question": "A 60-year-old female with Type 2 Diabetes Mellitus, ESRD on hemodialysis, and a history of latent TB infection (LTBI) is started on Isoniazid monotherapy for 9 months. She is also on various other medications, including pyridoxine 25 mg daily.",
    "options": {
      "A": "Pyridoxine supplementation is crucial due to her diabetes and renal disease, as both are risk factors for INH-induced neuropathy.",
      "B": "If she develops new-onset seizures, intravenous pyridoxine should be immediately administered.",
      "C": "A daily pyridoxine dose of 100 mg is unlikely to provide further benefit if neuropathy develops despite initial supplementation.",
      "D": "Other neurotoxic adverse effects, such as headaches or drowsiness, typically resolve with continuation of TB medications and supportive methods."
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The question asks for the LEAST accurate statement regarding the patient's management. This patient has multiple risk factors for INH-induced neurotoxicity (diabetes, ESRD on hemodialysis), making pyridoxine supplementation critical. Let's analyze each option:\n\n-   **A. Pyridoxine supplementation is crucial due to her diabetes and renal disease, as both are risk factors for INH-induced neuropathy.** The context states: 'Pyridoxine (25‑50 mg) is given with each INH dose to all persons at risk of neuropathy, including patients with diabetes, HIV, renal disease...' This statement is **ACCURATE**.\n-   **B. If she develops new-onset seizures, intravenous pyridoxine should be immediately administered.** The context states: 'Seizures... may develop as a result of INH toxicity... patients should be immediately hospitalized and treated with intravenous pyridoxine and antiepileptic drugs.' This statement is **ACCURATE**.\n-   **C. A daily pyridoxine dose of 100 mg is unlikely to provide further benefit if neuropathy develops despite initial supplementation.** The context states: 'For patients who develop neuropathy while on pyridoxine, doses may be increased to 100 mg daily; supplementation above this dose is unlikely to be helpful.' This implies that increasing the dose to 100 mg daily *is* the recommended step for benefit if neuropathy develops, while doses *above* 100 mg are unlikely to be helpful. Therefore, the statement that '100 mg is unlikely to provide further benefit' is **INACCURATE** and directly contradicts the recommendation to increase to 100 mg. This is the least accurate statement.\n-   **D. Other neurotoxic adverse effects, such as headaches or drowsiness, typically resolve with continuation of TB medications and supportive methods.** The context states: 'Other neurotoxic adverse effects typically resolve with continuation of TB medications and are best addressed with supportive methods.' This statement is **ACCURATE**.\n\nTherefore, statement C is the LEAST accurate.",
    "highYieldPearl": "Rio's Take: Pay close attention to subtle phrasing. For INH-induced neuropathy, 100 mg pyridoxine daily is the recommended therapeutic increase, not a dose 'unlikely to provide benefit'. The 'unlikely to be helpful' threshold is *above* 100 mg.",
    "examStyle": "INI-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This statement correctly identifies diabetes and renal disease as risk factors for INH neuropathy and the importance of pyridoxine supplementation, making it accurate.",
      "B": "This statement correctly identifies the emergency management of INH-induced seizures with IV pyridoxine, making it accurate.",
      "C": "This is the incorrect statement. The text explicitly states that doses *may be increased to 100 mg daily* if neuropathy develops. It's *supplementation above this dose* (i.e., >100 mg) that is unlikely to be helpful. This option misinterprets the 100 mg dose as being ineffective, when it is, in fact, the recommended therapeutic increase for established neuropathy.",
      "D": "This statement is directly supported by the text regarding the management of general neurotoxic adverse effects, making it accurate."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_da85a4de",
    "question": "A 45-year-old male with newly diagnosed pulmonary tuberculosis and Type 2 Diabetes Mellitus is started on a standard four-drug antitubercular regimen including isoniazid (INH). He was concurrently prescribed pyridoxine 25 mg daily due to his diabetes. After 6 weeks, he presents with numbness and tingling in his feet, consistent with peripheral neuropathy. His liver and renal function tests are stable. What is the most appropriate next step in his management?",
    "options": {
      "A": "Increase pyridoxine dose to 100 mg daily.",
      "B": "Discontinue isoniazid and substitute with ethambutol.",
      "C": "Reduce isoniazid dose by half.",
      "D": "Administer intravenous pyridoxine."
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Isoniazid (INH) causes a functional deficiency of pyridoxine (vitamin B6) which can lead to peripheral neuropathy. Patients with diabetes, HIV, renal disease, alcohol abuse, and other conditions are at higher risk and should receive pyridoxine supplementation (25-50 mg) with each INH dose. If a patient develops neuropathy while already on pyridoxine supplementation, the dose should be increased to 100 mg daily. Supplementation above this dose is generally not more effective. Discontinuing INH is usually a last resort for refractory or severe neuropathy. Intravenous pyridoxine is reserved for acute INH toxicity presenting with seizures or overdose.",
    "highYieldPearl": "Rio's Take: Always consider pyridoxine supplementation with INH, especially in high-risk groups. For established neuropathy on standard supplementation, increasing pyridoxine to 100 mg daily is the next step before considering INH discontinuation.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This is the correct management strategy for INH-induced neuropathy that develops despite initial pyridoxine supplementation, as per guidelines.",
      "B": "Discontinuing INH is usually too drastic a step when dose adjustment of pyridoxine is an option. Ethambutol is already part of the initial regimen and is not a substitute for INH in this context.",
      "C": "Reducing the INH dose might compromise the efficacy of the antitubercular regimen and is not the primary intervention for INH-induced neuropathy when pyridoxine can be adjusted.",
      "D": "Intravenous pyridoxine is indicated for acute severe INH toxicity, such as seizures or overdose, not for subacute peripheral neuropathy."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_56aab978",
    "question": "A 30-year-old male with HIV on antiretroviral therapy and a 2-month history of pulmonary tuberculosis on standard antitubercular treatment presents to the emergency department with altered sensorium and generalized tonic-clonic seizures. Laboratory investigations reveal severe metabolic acidosis with an elevated anion gap. His blood glucose is 110 mg/dL, and serum creatinine is 0.9 mg/dL. He denies alcohol intake. Which of the following is the most likely cause of his metabolic derangement and seizures?",
    "options": {
      "A": "Zidovudine-induced lactic acidosis.",
      "B": "Diabetic ketoacidosis.",
      "C": "Isoniazid toxicity.",
      "D": "Uremic acidosis."
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient presents with an acute neurological emergency (seizures, altered sensorium) combined with severe anion gap metabolic acidosis while on antitubercular treatment including isoniazid (INH). INH toxicity, particularly in overdose or severe reactions, can lead to seizures (including status epilepticus) and Type B lactic acidosis due to altered lactate metabolism without hypoxia. While zidovudine (AZT), an antiretroviral drug, can cause Type B lactic acidosis, the prominent feature of seizures points more strongly to acute INH toxicity as the primary etiology for the combined presentation. Normal blood glucose rules out diabetic ketoacidosis, and normal serum creatinine rules out uremic acidosis.",
    "highYieldPearl": "Rio's Take: In a patient on INH presenting with acute neurological symptoms like seizures and anion gap metabolic acidosis, always suspect INH toxicity. Immediate treatment with intravenous pyridoxine is critical.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Zidovudine is listed as a cause of Type B lactic acidosis, but the acute onset of seizures combined with acidosis makes INH toxicity a more likely and direct explanation for both symptoms.",
      "B": "Diabetic ketoacidosis is ruled out by the normal blood glucose level (110 mg/dL).",
      "C": "Isoniazid toxicity is strongly associated with both seizures and Type B lactic acidosis, making it the most unifying and likely diagnosis given the clinical picture and patient's medication history.",
      "D": "Uremic acidosis is ruled out by the normal serum creatinine level (0.9 mg/dL)."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_61a838ea",
    "question": "A 38-year-old male with known HIV infection, currently on stable antiretroviral therapy and being investigated for chronic cough, presents with a history of recurrent spontaneous pneumothorax. A recent high-resolution CT (HRCT) chest shows diffuse, thin-walled cysts of varying sizes, uniformly distributed across all lung fields, with some cysts showing internal septations. There are no associated nodules or ground-glass opacities. His CD4 count is 350 cells/µL. What is the most likely diagnosis?",
    "options": {
      "A": "Lymphangioleiomyomatosis (LAM).",
      "B": "Pulmonary Langerhans Cell Histiocytosis (PLCH).",
      "C": "Lymphoid Interstitial Pneumonia (LIP).",
      "D": "Birt-Hogg-Dubé syndrome (BHD)."
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient has HIV infection and presents with recurrent pneumothorax and diffuse, thin-walled cysts of varying sizes, uniformly distributed, with internal septations on HRCT. Lymphoid Interstitial Pneumonia (LIP) is strongly associated with HIV, and its characteristic CT findings include cysts of variable size, uniformly distributed across all lung fields (often with a slight lower-lobe predominance) and frequently showing internal septations. While recurrent pneumothorax can occur in LAM and BHD, LAM is predominantly seen in women and often associated with angiomyolipomas. BHD cysts are typically round-lentiform and basilar/subpleural, and also associated with renal tumors and skin lesions. PLCH is associated with smoking and typically shows bizarre-shaped cysts with upper lobe predominance and sparing of costophrenic angles.",
    "highYieldPearl": "Rio's Take: In a patient with HIV and cystic lung disease, LIP is a common consideration. Pay close attention to specific HRCT cyst morphology (size, distribution, septations) and associated extrapulmonary manifestations to differentiate between cystic lung diseases.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "While LAM can cause recurrent pneumothorax and diffuse cysts, it is far more common in women and typically associated with renal angiomyolipomas. The patient's sex and the specific description of internal septations make LIP more likely.",
      "B": "PLCH is typically linked to smoking and shows cysts with bizarre shapes, often with an upper-lobe predominance and costophrenic angle sparing, which does not match the 'uniformly distributed' description.",
      "C": "LIP is strongly associated with HIV and its HRCT features (variable-sized cysts, uniform distribution, internal septations) closely match the vignette.",
      "D": "BHD is characterized by basilar/subpleural cysts and associations with renal tumors and skin fibrofolliculomas, which are not described in the patient's presentation. The cyst distribution also differs from the uniform distribution described."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b077a471",
    "question": "A 45-year-old male recently diagnosed with pulmonary tuberculosis is initiated on standard antitubercular therapy including Isoniazid (INH). His medical history includes Type 2 Diabetes Mellitus. Which of the following co-prescriptions is essential to prevent a common adverse effect of INH in this high-risk patient?",
    "options": {
      "A": "Pyridoxine",
      "B": "Ethambutol",
      "C": "Prednisolone",
      "D": "Folic acid"
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Isoniazid (INH) causes a functional deficiency of pyridoxine (vitamin B6) which can lead to peripheral neuropathy. Patients with diabetes, HIV, renal disease, alcohol abuse, malnutrition, pregnancy, or advanced age are at high risk for developing this neuropathy. Therefore, pyridoxine supplementation (25-50 mg daily) is essential when prescribing INH to these patients to mitigate this adverse effect.",
    "highYieldPearl": "Rio's Take: Always consider pyridoxine supplementation with INH, especially in patients with diabetes, HIV, or renal impairment, to prevent neuropathy.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Correct. Pyridoxine (Vitamin B6) supplementation is crucial to prevent INH-induced peripheral neuropathy, particularly in high-risk groups like diabetic patients.",
      "B": "Ethambutol is another antitubercular drug and not a supplement to prevent INH side effects. Co-prescribing it without indication for the given purpose is incorrect.",
      "C": "Prednisolone is a corticosteroid sometimes used in severe forms of TB (e.g., TB meningitis, pericarditis) or drug-induced hypersensitivity, but not routinely given to prevent INH-induced neuropathy.",
      "D": "Folic acid is essential for various metabolic processes and is supplemented in conditions like megaloblastic anemia or during pregnancy, but it is not directly related to preventing INH-induced neuropathy."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b264d085",
    "question": "A 60-year-old patient with chronic kidney disease on hemodialysis, receiving antitubercular therapy including Isoniazid (INH), develops generalized tonic-clonic seizures. Emergency medical services are called. Based on the most likely cause related to his therapy, what is the most appropriate immediate pharmacological intervention for INH-induced seizures in the emergency setting?",
    "options": {
      "A": "Intravenous Diazepam",
      "B": "Intravenous Phenytoin",
      "C": "Intravenous Pyridoxine",
      "D": "Oral Levetiracetam"
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Seizures, including status epilepticus, can develop as a result of Isoniazid (INH) toxicity, especially in high-risk patients like those with renal disease. The immediate and specific treatment for INH-induced seizures involves intravenous pyridoxine, often in conjunction with antiepileptic drugs. Pyridoxine reverses the INH-induced GABA deficiency that leads to seizures.",
    "highYieldPearl": "Rio's Take: INH-induced seizures are a medical emergency requiring immediate IV pyridoxine, alongside conventional antiepileptic drugs.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Intravenous Diazepam is a benzodiazepine used to terminate acute seizures. While it may be used as an adjunct, it is not the specific antidote for INH-induced seizures.",
      "B": "Intravenous Phenytoin is a commonly used antiepileptic drug for seizure control. However, like diazepam, it does not address the underlying INH-induced pyridoxine deficiency, making IV pyridoxine the more specific and immediate primary intervention for INH toxicity.",
      "C": "Correct. Intravenous Pyridoxine is the specific antidote for INH-induced seizures, directly counteracting the neurotoxic effect by restoring GABA synthesis.",
      "D": "Oral Levetiracetam is an antiepileptic drug used for seizure management. Oral administration is not suitable for immediate emergency treatment of ongoing seizures, and it does not specifically address INH toxicity."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_5eed7dd6",
    "question": "A 55-year-old male with HIV infection is admitted to the hospital with altered sensorium and severe metabolic acidosis. Laboratory investigations reveal a high anion gap. He is currently on antitubercular therapy including Isoniazid (INH). Which of the following is a recognized cause of Type B lactic acidosis highly relevant to this patient's clinical scenario?",
    "options": {
      "A": "Diabetic ketoacidosis",
      "B": "Uremia",
      "C": "Isoniazid toxicity",
      "D": "Methanol poisoning"
    },
    "correctAnswer": "C",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "Type B lactic acidosis refers to altered lactate metabolism without hypoxia. Several conditions and drugs can cause it. The provided text explicitly lists HIV and isoniazid toxicity among the causes of Type B lactic acidosis. Since the patient has HIV and is on INH, INH toxicity is a direct and highly relevant cause from the given options for Type B lactic acidosis in this specific clinical context.",
    "highYieldPearl": "Rio's Take: Remember that both HIV infection and Isoniazid toxicity are recognized causes of Type B lactic acidosis.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Diabetic ketoacidosis is a form of ketoacidosis, not lactic acidosis, although it also presents with a high anion gap. The question specifically asks for Type B lactic acidosis.",
      "B": "Uremia is a cause of high anion gap acidosis, but it is listed as a separate category ('UREMIA') and not specifically as a cause of Type B lactic acidosis in the provided text's classification.",
      "C": "Correct. Isoniazid toxicity is explicitly listed as a drug cause of Type B lactic acidosis. Given the patient's ongoing antitubercular therapy, this is a highly relevant cause.",
      "D": "Methanol poisoning causes a high anion gap acidosis due to toxic anions (formate) but is classified under 'TOXIC ANIONS' and not specifically as Type B lactic acidosis in the provided context, nor is it suggested by the patient's history."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_42d68a40",
    "question": "A 45-year-old male with a history of HIV infection (on ART) and poorly controlled type 2 diabetes mellitus is diagnosed with smear-positive pulmonary tuberculosis. He is initiated on a standard four-drug anti-tubercular regimen including Isoniazid (INH). Three weeks later, he presents to the emergency department with generalized tonic-clonic seizures and altered sensorium. Initial laboratory investigations reveal severe metabolic acidosis with an elevated anion gap. His other anti-tubercular medications have been held. \n\nWhat is the most appropriate immediate pharmacological intervention for this patient's acute presentation?",
    "options": {
      "A": "Intravenous Pyridoxine",
      "B": "Intravenous Lorazepam",
      "C": "Sodium Bicarbonate infusion",
      "D": "Levetiracetam loading dose"
    },
    "correctAnswer": "A",
    "topic": "TB in HIV, Renal Failure, Diabetes",
    "deepDiveExplanation": "The patient's clinical presentation, including generalized tonic-clonic seizures and elevated anion gap metabolic acidosis, in the context of Isoniazid (INH) treatment and significant risk factors (HIV, diabetes), is highly suggestive of acute INH toxicity. INH overdose or toxicity leads to a functional pyridoxine (vitamin B6) deficiency, impairing the synthesis of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter, which precipitates seizures. Additionally, INH toxicity can cause Type B lactic acidosis, contributing to the elevated anion gap metabolic acidosis.\n\nThe provided context explicitly states that for seizures resulting from INH toxicity (including overdoses), patients should be immediately hospitalized and treated with intravenous pyridoxine and antiepileptic drugs. Pyridoxine directly counteracts INH's neurotoxic effects by restoring pyridoxine-dependent enzyme activity, thereby facilitating GABA synthesis. While antiepileptic drugs like benzodiazepines are crucial for the immediate termination of acute seizures, intravenous pyridoxine is the specific antidote that addresses the underlying cause of INH neurotoxicity and contributes to resolving the metabolic derangement, making it the most appropriate and comprehensive pharmacological intervention for the overall acute presentation.",
    "highYieldPearl": "Rio's Take: Acute INH toxicity, especially in high-risk patients like those with HIV, diabetes, or renal disease, commonly manifests as seizures and elevated anion gap lactic acidosis. Intravenous pyridoxine is the specific antidote, vital for reversing the underlying biochemical defect and should be administered immediately, often alongside symptomatic antiseizure medications.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This is the correct answer. Intravenous pyridoxine is the specific antidote for INH-induced neurotoxicity, directly addressing the underlying functional pyridoxine deficiency that causes seizures. It also aids in resolving the associated lactic acidosis, making it the most comprehensive immediate pharmacological intervention for the patient's acute presentation.",
      "B": "This is a strong plausible trap. Intravenous lorazepam, a benzodiazepine, is the first-line treatment for terminating acute generalized tonic-clonic seizures. While essential for immediate seizure control to prevent cerebral hypoxia and injury, it is symptomatic treatment and does not address the root cause of INH toxicity or the associated metabolic acidosis. In toxicological emergencies where a specific antidote exists, the antidote is often considered the 'most appropriate' intervention for the overall acute presentation, even if symptomatic control is given concurrently.",
      "C": "This is a plausible trap. Sodium bicarbonate infusion is used to correct severe metabolic acidosis. While the patient has severe metabolic acidosis, this is supportive therapy and does not treat the underlying INH toxicity causing the lactic acidosis. Addressing the cause with pyridoxine is paramount.",
      "D": "This is a less likely trap. Levetiracetam is an antiepileptic drug used for seizure management but is typically not the immediate first-line agent for acute status epilepticus compared to rapidly acting benzodiazepines. Like lorazepam, it also does not address the specific INH toxicity."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_ebf0bdde",
    "question": "A 48-year-old male, who underwent allogeneic hematopoietic cell transplantation (HCT) 18 months ago for acute myeloid leukemia, presents with persistent cough, low-grade fever, and progressive dyspnea for the past 2 months. His post-transplant course was complicated by severe chronic graft-versus-host disease (GVHD) requiring prolonged immunosuppression, and a recent episode of cytomegalovirus (CMV) viremia treated 3 months prior. Chest CT scan reveals cavitary lesions and extensive bronchiectasis in the upper lobes. Despite broad-spectrum antibiotics, his symptoms persist. Which of the following categories of infection is most consistent with this patient's current presentation?",
    "options": {
      "A": "Non-tuberculous Mycobacteria (NTM) infection",
      "B": "Active Mycobacterium tuberculosis infection",
      "C": "Invasive fungal pneumonia",
      "D": "Bacterial superinfection in chronic GVHD lung disease"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with chronic respiratory symptoms, cavitary lesions, and bronchiectasis, occurring 18 months post-allogeneic HCT, points strongly towards a late-onset opportunistic infection. The provided text explicitly highlights NTM pulmonary infections as increasingly recognized 'late infectious problems' in HCT recipients, with a median onset of 343 days post-HCT. Furthermore, NTM infections in HCT are specifically associated with severe chronic GVHD and CMV viremia, both of which are present in this patient's history. While *M. tuberculosis* can cause cavitary lesions, its incidence in HCT is low (0.23-0.79%), and the constellation of late onset, chronic GVHD, and CMV viremia makes NTM infection a more likely consideration in this specific context. Invasive fungal pneumonia is possible, but the question asks for the *most consistent category* given the specific NTM risk factors and timing mentioned in the text. Bacterial superinfection is less likely to cause such persistent symptoms and cavitary lesions despite broad-spectrum antibiotics without other compelling evidence.",
    "highYieldPearl": "Rio's Take: NTM pulmonary infections are important late complications in HCT, particularly in patients with chronic GVHD and CMV viremia, and should be considered for chronic respiratory symptoms and characteristic imaging like bronchiectasis or cavitation.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "Correct. This aligns with the text's description of NTM as a late-onset problem (18 months post-HCT), associated with severe chronic GVHD and CMV viremia, commonly presenting as lung disease with bronchiectasis and cavitation.",
      "B": "Plausible as TB can cause cavitary lesions and affects immunocompromised individuals. However, the text emphasizes TB's rarity in HCT (0.23-0.79%) and does not link it to the specific risk factors of severe chronic GVHD and CMV viremia as strongly as it does NTM. This option is a common distractor in mycobacterial questions.",
      "C": "Plausible, as fungal infections are common in HCT recipients and can cause similar imaging findings. However, the question asks for the *most consistent category* given the specific risk factors and timing highlighted for NTM in the provided text. The vignette does not offer specific fungal risk factors beyond general immunosuppression.",
      "D": "Plausible, as chronic lung disease post-HCT can lead to recurrent bacterial infections. However, the persistence despite broad-spectrum antibiotics and the presence of cavitary lesions suggest a more specific opportunistic pathogen than a typical bacterial superinfection."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_01853fc0",
    "question": "A 62-year-old female, with a history of interstitial lung disease and chronic cough for several months, undergoes a bronchoalveolar lavage (BAL) for diagnostic evaluation. Initial routine bacterial and fungal cultures are negative. Given her clinical course, a diagnosis of NTM infection is strongly suspected. The clinician is considering advanced molecular testing, specifically Next-Generation Sequencing (NGS), to expedite diagnosis. Which of the following statements regarding NGS for NTM diagnosis is most accurate based on current understanding?",
    "options": {
      "A": "NGS typically offers higher sensitivity for NTM detection compared to traditional mycobacterial cultures, especially in cases of low bacterial burden.",
      "B": "The low abundance of NTM DNA in respiratory samples may result in NGS having inadequate sensitivity when compared to traditional mycobacterial culture.",
      "C": "NGS is primarily valuable for identifying antimicrobial resistance patterns in NTM, with limited utility for initial pathogen detection.",
      "D": "For NTM, NGS is recommended as the first-line diagnostic test due to its comprehensive pathogen identification and rapid turnaround time."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided text explicitly states, 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This highlights a significant limitation of NGS for NTM diagnosis, making traditional culture often more sensitive despite the promise of molecular methods. Therefore, the low abundance of NTM DNA in samples is a critical factor impacting NGS sensitivity for detection.",
    "highYieldPearl": "Rio's Take: While NGS is a powerful tool, its sensitivity for NTM detection may be limited by the often low DNA abundance of NTM in clinical samples, potentially making traditional mycobacterial cultures more sensitive for initial diagnosis.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is a common misconception about molecular diagnostics in general, but specifically contradicted by the provided text regarding NTM. NGS sensitivity for NTM can be *lower* due to low DNA abundance.",
      "B": "Correct. This statement directly reflects the information provided in the text, emphasizing the challenge of NTM DNA abundance impacting NGS sensitivity for pathogen detection.",
      "C": "While NGS is indeed valuable for resistance profiling, the statement 'limited utility for initial pathogen detection' for NTM is too strong and not fully supported as a primary limitation in the context of the question. The primary limitation mentioned in the text for *detection* is the low DNA abundance leading to inadequate sensitivity compared to culture.",
      "D": "This is incorrect. Despite the advantages of NGS, the text indicates its potential inadequacy in sensitivity for NTM detection, implying it is not universally recommended as a first-line diagnostic for NTM over cultures. Cultures remain essential."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_fb69521a",
    "question": "A 55-year-old female presents with persistent cough, fatigue, and occasional hemoptysis over 8 months. She denies any known TB exposure. Her medical history includes well-controlled asthma. A chest CT scan reveals extensive bilateral bronchiectasis with tree-in-bud opacities, predominantly in the right middle lobe and lingula. Sputum acid-fast bacilli (AFB) smears are positive, and cultures are pending. Considering the radiographic findings and her clinical presentation, which of the following statements is most appropriate at this stage?",
    "options": {
      "A": "Given the characteristic radiographic findings, empiric multi-drug therapy for active Mycobacterium tuberculosis should be initiated immediately.",
      "B": "The radiographic pattern of bronchiectasis is highly suggestive of NTM infection, necessitating speciation of the mycobacteria prior to targeted therapy.",
      "C": "The presence of tree-in-bud opacities indicates active primary tuberculosis, overriding other diagnostic considerations.",
      "D": "A negative interferon-gamma release assay (IGRA) would reliably rule out mycobacterial disease in this immunocompetent patient."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with chronic cough, hemoptysis, and specific CT findings (extensive bilateral bronchiectasis with tree-in-bud opacities, especially in the right middle lobe and lingula) in an individual with well-controlled asthma and no TB exposure is highly suggestive of NTM pulmonary disease. The provided text states that 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' While positive AFB smears warrant consideration of *M. tuberculosis*, the typical radiographic pattern of NTM (bronchiectasis, particularly in RML/lingula, and tree-in-bud) makes NTM a very strong differential. Since treatment regimens for NTM and *M. tuberculosis* differ significantly, awaiting speciation of the mycobacteria from culture is crucial for guiding appropriate targeted therapy.",
    "highYieldPearl": "Rio's Take: When confronted with chronic respiratory symptoms, positive AFB smears, and a CT showing bronchiectasis (especially in RML/lingula) and tree-in-bud opacities, NTM should be a prime suspect. Speciation of mycobacteria is critical before initiating definitive therapy, as NTM and TB treatments differ.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "While positive AFB smears usually prompt empiric TB therapy, the *specific radiographic pattern* (extensive bronchiectasis in RML/lingula, chronic symptoms) makes NTM a very strong possibility. Starting standard TB therapy empirically when NTM is highly suspected (and common) may delay appropriate NTM treatment and expose the patient to unnecessary drugs. Speciation is paramount.",
      "B": "Correct. This statement accurately captures the diagnostic challenge. Bronchiectasis is a common finding in NTM disease, and given the patient's history, NTM is a significant possibility. Speciation is critical to differentiate NTM from TB and identify the specific NTM species, which then guides therapy.",
      "C": "Incorrect. Tree-in-bud opacities signify endobronchial spread of infection and can be seen in various conditions, including NTM infections, not exclusively active primary tuberculosis. This option presents a definitive statement that is medically inaccurate in this context.",
      "D": "Incorrect. IGRA is primarily used for diagnosing latent TB infection (LTBI) and cannot distinguish between latent and active disease. While it might be useful in some active TB cases, a negative result does not reliably rule out *active* mycobacterial disease, especially NTM, which is not detected by TB-specific IGRAs. The patient has positive AFB smears, indicating active infection, making IGRA less relevant for ruling out the already detected mycobacteria."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_e1b9196d",
    "question": "A 45-year-old male who underwent allogeneic hematopoietic cell transplantation 1.5 years ago for acute myeloid leukemia presents with a 4-month history of productive cough, progressive dyspnea, and recurrent low-grade fever. He has a history of severe chronic graft-versus-host disease (GVHD) affecting his skin and liver, for which he is on prolonged immunosuppression. His chest CT scan reveals new-onset multifocal bronchiectasis with scattered centrilobular nodules. Sputum acid-fast bacilli (AFB) stain is positive.",
    "options": {
      "A": "Mycobacterium avium complex (MAC)",
      "B": "Mycobacterium tuberculosis",
      "C": "Nocardia farcinica",
      "D": "Aspergillus fumigatus"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with a late-onset (1.5 years post-HCT) pulmonary infection, multifocal bronchiectasis on CT scan, positive AFB smear, and a history of chronic GVHD strongly points towards Nontuberculous Mycobacteria (NTM) infection. The provided context states that NTMs are increasingly recognized as a late infectious problem in HCT, with the vast majority presenting with lung disease at a median time of 343 days post-HCT (this patient is at ~547 days). It also explicitly links NTM with severe chronic GVHD and mentions that 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' Mycobacterium avium complex (MAC) is the most common NTM species causing pulmonary disease.",
    "highYieldPearl": "Rio's Take: NTM pulmonary infections are a recognized late complication in HCT recipients, particularly in those with chronic GVHD, and often manifest with bronchiectasis on imaging.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This option aligns with the clinical vignette: late presentation post-HCT, presence of chronic GVHD, and characteristic CT findings (bronchiectasis) are all hallmarks of NTM infection as described in the context.",
      "B": "While *Mycobacterium tuberculosis* can cause disease in immunocompromised patients, the context highlights that active TB is rare in HCT recipients (0.23–0.79%) compared to NTM (2.7% in a cohort). Furthermore, the specific radiographic finding of multifocal bronchiectasis is more consistently linked to NTM disease than typical TB in the provided text, which associates TB more with parenchymal disease, cavitation, or lymphadenopathy.",
      "C": "*Nocardia farcinica* can cause chronic pulmonary infections in immunocompromised hosts and can be partially acid-fast, potentially leading to a positive AFB smear. However, the strong association of chronic GVHD and bronchiectasis with NTM in HCT recipients, as detailed in the text, makes NTM a more direct and specific answer based on the provided information.",
      "D": "*Aspergillus fumigatus* is a common fungal pathogen in HCT recipients, but it is not acid-fast and typically presents with different radiographic features (e.g., halo sign, air crescent sign) rather than multifocal bronchiectasis as a primary pattern. A positive AFB smear rules out Aspergillus as the primary mycobacterial pathogen."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_c479f363",
    "question": "A 62-year-old female with a history of severe COPD and prior tuberculosis presents with slowly progressive cough, sputum production, and weight loss over several months. Her chest CT scan shows extensive bronchiectasis in the right middle lobe and lingula. Sputum samples are sent for microbiological evaluation, including acid-fast bacilli (AFB) culture and next-generation sequencing (NGS) analysis. The NGS report indicates a very low abundance of Mycobacterium abscessus DNA, near the limit of detection, while the AFB culture results are pending.",
    "options": {
      "A": "The low abundance of NTM DNA by NGS suggests active NTM disease is unlikely, and further treatment decisions should await culture results.",
      "B": "NGS with low NTM DNA abundance is highly sensitive and diagnostic for active NTM disease, warranting immediate initiation of targeted therapy.",
      "C": "NGS may have inadequate sensitivity compared to cultures for NTM, so clinical suspicion should remain high despite low DNA abundance.",
      "D": "The presence of any NTM DNA by NGS, regardless of abundance, confirms NTM infection and justifies empirical NTM treatment."
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided context explicitly states that for NTM, 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' Given the patient's strong clinical picture (COPD, bronchiectasis, chronic symptoms suggestive of NTM), the low NGS signal should not be interpreted as ruling out NTM. Instead, it highlights a limitation of NGS for NTM, and clinical suspicion should persist while awaiting culture results, which are considered more sensitive for NTM detection.",
    "highYieldPearl": "Rio's Take: NGS has known limitations in sensitivity for NTM, often yielding low DNA abundance even in active disease. Clinical and radiological findings remain crucial in NTM diagnosis.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This option is a plausible trap because in many infectious diseases, low DNA abundance by molecular methods might suggest low pathogen burden or unlikely active disease. However, the provided text directly contradicts this interpretation for NTM, stating NGS often has 'inadequate sensitivity' and NTM DNA can have 'low abundance' even when causative, making it misleading to dismiss active disease based solely on this finding.",
      "B": "This is incorrect. The text specifically states that NGS may have 'inadequate sensitivity' for NTM, meaning low abundance is not indicative of high sensitivity or immediate definitive diagnosis for active disease. NTM diagnosis requires a combination of clinical, radiological, and microbiological criteria, typically involving repeated positive cultures.",
      "C": "This is the correct interpretation based on the provided context. The text directly states that low NTM DNA abundance is a characteristic finding and suggests 'inadequate sensitivity compared to cultures for NTM.' Therefore, high clinical suspicion is warranted given the patient's symptoms and CT findings of bronchiectasis, which is consistent with NTM disease.",
      "D": "This overstates the diagnostic utility of NGS for NTM. While any NTM DNA might raise suspicion, the text's emphasis on low abundance and inadequate sensitivity means that NGS alone, especially with low abundance, does not automatically confirm infection or justify empirical treatment without further confirmatory evidence, such as culture results and adherence to diagnostic criteria."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_9ae0f278",
    "question": "A 58-year-old male kidney transplant recipient, maintained on tacrolimus and mycophenolate mofetil, is diagnosed with pulmonary Mycobacterium kansasii infection based on consistent symptoms, cavitary lung lesions on CT, and multiple positive sputum cultures. He requires initiation of anti-mycobacterial therapy, which is likely to include a rifamycin.",
    "options": {
      "A": "Avoiding all rifamycins due to an unacceptable risk of tacrolimus-related nephrotoxicity.",
      "B": "Anticipating the need for significant tacrolimus dose adjustments if rifampin is used, and closely monitoring for allograft rejection.",
      "C": "Substituting pyrazinamide with ethambutol to minimize drug-drug interactions with tacrolimus.",
      "D": "Prioritizing isoniazid-based regimens to prevent any interaction with his immunosuppressants."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The context highlights that 'The use of rifampin can be problematic due to the increased risk of hepatotoxicity and the induction of cytochrome P450 isoenzymes, which can reduce serum concentrations of several immunosuppressants and azole antifungals, potentially leading to allograft rejection and infection.' It specifically advises: 'During rifampin treatment, doses of the immunosuppressants cyclosporine, tacrolimus, and sirolimus must be increased and signs of rejection closely monitored.' Since *Mycobacterium kansasii* treatment typically involves a rifamycin (often rifampin), careful management of tacrolimus levels and monitoring for rejection are critical due to this potent drug interaction.",
    "highYieldPearl": "Rio's Take: Rifampin significantly induces CYP450, leading to reduced levels of calcineurin inhibitors (e.g., tacrolimus) in transplant recipients, necessitating dose escalation and close monitoring for allograft rejection.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This is incorrect. While rifampin has significant interactions, avoiding all rifamycins is often not feasible or optimal given their potent anti-mycobacterial activity and necessity in many NTM regimens. The issue is managing the interaction, not complete avoidance. The primary concern is *decreased* tacrolimus levels leading to rejection, not primarily increased tacrolimus-related nephrotoxicity (though mismanaged high tacrolimus doses could lead to it).",
      "B": "This is the correct action. The context explicitly states that rifampin induces CYP450, leading to reduced levels of immunosuppressants like tacrolimus, and mandates increasing doses of these immunosuppressants and monitoring for rejection during rifampin treatment.",
      "C": "This is a distracter. The context focuses specifically on rifampin's interaction with immunosuppressants via CYP450 induction. While all medications have potential interactions, there is no specific mention in the provided text of pyrazinamide or ethambutol having a critical interaction with tacrolimus that would necessitate such a substitution specifically to minimize drug-drug interactions with tacrolimus.",
      "D": "While isoniazid has fewer drug interactions with immunosuppressants compared to rifampin, *M. kansasii* infection typically requires a multi-drug regimen that includes a rifamycin for optimal efficacy. The prompt states the therapy is 'likely to include a rifamycin,' making prioritizing an isoniazid-only based regimen (which would be insufficient) inappropriate. The context also mentions rifampin's potent activity, and rifabutin as an alternative, implying the continued need for a rifamycin in mycobacterial treatment."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_57e5ac2b",
    "question": "A 55-year-old male who underwent allogeneic hematopoietic cell transplantation 1.5 years ago for acute myeloid leukemia presents with a 2-month history of worsening cough, exertional dyspnea, and recurrent low-grade fever. He has severe chronic graft-versus-host disease (cGVHD) affecting the skin and gut, for which he is on prolonged immunosuppression. His last CMV PCR 3 months ago was positive, but he completed a course of valganciclovir. Chest CT shows new multi-lobar bronchiectasis with tree-in-bud opacities. Sputum acid-fast bacilli (AFB) stain is negative. Which of the following is the *most likely* causative pathogen, given the clinical context?",
    "options": {
      "A": "Nontuberculous Mycobacteria (NTM)",
      "B": "Mycobacterium tuberculosis (MTB)",
      "C": "Pneumocystis jirovecii",
      "D": "Cytomegalovirus (CMV)"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's clinical presentation is highly suggestive of NTM pulmonary disease in an allogeneic HCT recipient. NTM infections are increasingly recognized as a late infectious problem in HCT, with a median onset of 343 days post-transplant. The patient is 1.5 years post-transplant, fitting this timeline. NTM in HCT is strongly associated with severe chronic GVHD and a history of CMV viremia, both of which are present in this patient. Radiologically, multi-lobar bronchiectasis with tree-in-bud opacities are classic findings consistent with NTM disease. While the AFB stain was negative, NTM can still be present, and culture remains the definitive diagnostic method.",
    "highYieldPearl": "Rio's Take: In HCT recipients presenting with late-onset chronic respiratory symptoms, especially with chronic GVHD or prior CMV viremia, and imaging showing bronchiectasis with tree-in-bud opacities, NTM should be high on the differential. NTM prevalence post-HCT (2.7%) is significantly higher than active TB (0.23–0.79%) in this population.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is the most accurate option. The combination of late post-HCT presentation, risk factors (cGVHD, CMV viremia), and classic radiological findings (bronchiectasis, tree-in-bud) strongly points towards NTM. The text explicitly mentions NTM as a 'late infectious problem' associated with these factors and that 'bronchiectasis may be consistent with NTM disease.'",
      "B": "Active TB is rare in HCT recipients (0.23–0.79%), even in low-endemicity regions. While TB can present with bronchiectasis, the overall epidemiology and the explicit mention of NTM as a growing late problem in HCT make NTM more likely. The negative AFB stain does not completely rule out MTB but weakens its likelihood as a 'most likely' option given other stronger indicators for NTM.",
      "C": "Pneumocystis jirovecii pneumonia (PCP) typically presents subacutely with dyspnea and hypoxemia, and imaging usually shows diffuse ground-glass opacities, not primarily bronchiectasis. Although possible in immunosuppressed patients, the imaging is less typical for PCP compared to NTM.",
      "D": "CMV pneumonitis can occur in HCT recipients, especially with prior viremia, but typically presents with diffuse interstitial infiltrates or ground-glass opacities, rather than pronounced bronchiectasis and tree-in-bud pattern. While CMV viremia is a risk factor for NTM, CMV itself is less likely to be the direct cause of this specific radiological pattern."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_592c84a9",
    "question": "A 48-year-old female with known cystic fibrosis presents with a 6-month history of persistent cough productive of purulent sputum, occasional hemoptysis, and weight loss. Prior sputum cultures have repeatedly grown *Pseudomonas aeruginosa* but have shown no growth of *Mycobacterium tuberculosis* or common bacteria. High-resolution CT chest reveals extensive bilateral bronchiectasis with multiple small centrilobular nodules. Given the suspicion of NTM infection, the pulmonologist is considering various diagnostic approaches. Which of the following statements regarding the diagnosis of NTM infection in this patient is *most accurate*?",
    "options": {
      "A": "Next-generation sequencing (NGS) of sputum is expected to have higher sensitivity for NTM detection compared to traditional mycobacterial cultures.",
      "B": "A positive acid-fast bacilli (AFB) smear from sputum is sufficient to diagnose NTM pulmonary disease and differentiate it from *M. tuberculosis*.",
      "C": "Repeated isolation of a specific NTM species from sputum cultures, along with compatible clinical and radiological findings, is crucial for diagnosis.",
      "D": "Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy is typically not required if sputum cultures are persistently negative for NTM."
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The diagnosis of NTM pulmonary disease relies on a combination of clinical, radiological, and microbiological criteria. According to established guidelines (e.g., ATS/IDSA), repeat isolation of the same NTM species from appropriate respiratory samples, along with compatible clinical symptoms and radiological findings (such as bronchiectasis or nodules), is crucial. This approach ensures that NTM is truly causing disease and not merely colonizing the airways.",
    "highYieldPearl": "Rio's Take: For NTM diagnosis, cultures are generally more sensitive than NGS due to the low abundance of NTM DNA. Diagnosis requires a holistic approach: repeated positive cultures, compatible clinical picture, and suggestive imaging. A single positive culture or a positive AFB smear is insufficient for diagnosis.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This statement is incorrect. The provided text explicitly states, 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This makes traditional culture the more sensitive method.",
      "B": "This statement is incorrect. A positive AFB smear indicates the presence of acid-fast bacilli but cannot differentiate between *M. tuberculosis* and various NTM species. Further speciation, typically by culture and molecular methods, is required for a definitive diagnosis and to guide treatment.",
      "C": "This statement is correct and reflects the standard diagnostic approach for NTM pulmonary disease. Due to NTM's potential for colonization, repeated isolation of the same species from multiple samples, combined with a consistent clinical picture and radiological findings, is essential to confirm active infection.",
      "D": "This statement is incorrect. If sputum cultures are persistently negative but there is a strong clinical and radiological suspicion for NTM, bronchoscopy with BAL and/or biopsy is often a necessary next step to obtain adequate samples for mycobacterial culture and histological examination, especially if the patient is unable to produce sputum or if deeper tissue samples are needed."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_d52c0450",
    "question": "A 62-year-old lung transplant recipient, currently on tacrolimus and mycophenolate mofetil for immunosuppression, is diagnosed with pulmonary NTM disease caused by *Mycobacterium avium* complex (MAC). The planned treatment regimen includes a macrolide (azithromycin), ethambutol, and a rifamycin. Considering the patient's transplant status and current medications, which of the following is the *most appropriate* approach for initiating NTM therapy?",
    "options": {
      "A": "Start the standard MAC regimen including rifampin, while closely monitoring tacrolimus levels and adjusting its dose as needed.",
      "B": "Substitute rifampin with rifabutin in the regimen and monitor tacrolimus levels due to potential, albeit weaker, drug interaction.",
      "C": "Withhold the rifamycin component entirely to avoid any interaction with tacrolimus, and proceed with macrolide and ethambutol only.",
      "D": "Switch the immunosuppression entirely from tacrolimus to an mTOR inhibitor like sirolimus before initiating any NTM treatment."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided context explicitly discusses the challenges of using rifampin in solid-organ transplant recipients due to its potent induction of cytochrome P450 isoenzymes, which can significantly reduce concentrations of immunosuppressants like tacrolimus, potentially leading to allograft rejection. It highlights that 'rifabutin may be preferable because it is a less potent inducer of cytochrome P450.' Therefore, substituting rifampin with rifabutin is the most appropriate strategy to minimize drug interactions while still providing a critical rifamycin component for effective NTM treatment. Monitoring tacrolimus levels remains essential with rifabutin, as it is still an inducer, albeit weaker.",
    "highYieldPearl": "Rio's Take: In transplant patients requiring rifamycin therapy, rifabutin is generally preferred over rifampin due to its less potent cytochrome P450 induction, which mitigates significant drug interactions with calcineurin inhibitors (like tacrolimus and cyclosporine) and mTOR inhibitors (like sirolimus). Close monitoring of immunosuppressant levels is still crucial.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "While it is true that tacrolimus levels must be closely monitored and increased when rifampin is used, the text explicitly states that 'rifabutin may be preferable' due to its less potent P450 induction. Therefore, starting with rifampin is not the *most appropriate* initial approach when a safer alternative exists.",
      "B": "This is the most appropriate approach. The text clearly indicates that rifabutin is a 'less potent inducer of cytochrome P450' and 'may be preferable' over rifampin in transplant patients on immunosuppressants. Monitoring tacrolimus is still necessary because rifabutin, while weaker, can still induce P450.",
      "C": "Rifamycins are a cornerstone of multi-drug regimens for MAC disease, and withholding this component would significantly compromise treatment efficacy and increase the risk of treatment failure or development of resistance. This is not a clinically acceptable strategy.",
      "D": "Switching immunosuppression is a drastic measure with its own risks, including allograft rejection or new toxicities, and is not a standard approach solely to manage a drug interaction that can be addressed by choosing an alternative rifamycin. Moreover, sirolimus (an mTOR inhibitor) also interacts with rifamycins, making this switch ineffective at avoiding the core issue, and potentially worsening it."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_08c5d5ee",
    "question": "A 55-year-old male underwent allogeneic hematopoietic cell transplantation (HCT) 1.5 years ago for acute myeloid leukemia. He has been on immunosuppressants for chronic graft-versus-host disease (GVHD) affecting his skin and liver. He presents with a 3-month history of productive cough, dyspnea, and weight loss. Chest CT shows new multi-lobar bronchiectasis with tree-in-bud opacities. His recent cytomegalovirus (CMV) viral load was detectable but low. Given his history, which of the following is the most likely associated factor for the suspected etiology?",
    "options": {
      "A": "Severe chronic GVHD",
      "B": "Early post-transplant period",
      "C": "High dose fluoroquinolone prophylaxis",
      "D": "T-helper type 1 immune upregulation"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's clinical presentation, including late onset (1.5 years post-HCT), chronic respiratory symptoms, and radiological findings (bronchiectasis, tree-in-bud opacities), is highly suggestive of nontuberculous mycobacterial (NTM) pulmonary disease. The provided context explicitly states that NTMs are increasingly recognized as a late infectious problem after HCT, with a median onset of 343 days post-HCT, and that NTM infections are associated with severe chronic GVHD and CMV viremia. The presence of chronic GVHD requiring immunosuppression makes the patient particularly vulnerable to opportunistic infections like NTM.",
    "highYieldPearl": "Rio's Take: In HCT recipients, consider NTM as a late-onset pulmonary complication, especially in patients with chronic GVHD or CMV viremia, presenting with chronic cough and infiltrates/bronchiectasis.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Correct. The context specifically links NTM infections in HCT to severe chronic GVHD and CMV viremia. The patient's history fits this description.",
      "B": "Incorrect. NTM infections are described as 'uncommon, particularly in the early post-transplant period' and are recognized as a 'late infectious problem' (median 343 days). 1.5 years post-HCT is a late presentation.",
      "C": "Incorrect. Fluoroquinolone prophylaxis is mentioned in the context of preventing active tuberculosis (TB), not as an associated factor for NTM infection. Its role in NTM is not discussed here, and it's generally not considered a risk factor for NTM.",
      "D": "Incorrect. T-helper type 1 immune upregulation during transplant conditioning is hypothesized to protect against active TB infection, not to be associated with NTM disease. Immunosuppression for GVHD would likely diminish T-helper type 1 responses."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_4e8d8804",
    "question": "A 68-year-old female with a history of COPD and long-standing cough presents with worsening exertional dyspnea and hemoptysis. Chest CT reveals extensive bronchiectasis predominantly in the right middle lobe and lingula, with multiple small centrilobular nodules. Sputum acid-fast bacilli (AFB) smears are positive on three separate occasions. To expedite diagnosis, an initial next-generation sequencing (NGS) analysis of her sputum comes back negative for NTM. What is the most appropriate next diagnostic step?",
    "options": {
      "A": "Initiate empiric broad-spectrum antibiotics and repeat NGS in 2 weeks.",
      "B": "Proceed with mycobacterial cultures and species identification.",
      "C": "Perform a transbronchial biopsy for histopathology.",
      "D": "Discontinue further NTM workup due to negative NGS."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's clinical picture (COPD, chronic cough, hemoptysis), radiological findings (extensive bronchiectasis, centrilobular nodules), and repeatedly positive AFB smears strongly suggest NTM pulmonary disease. The provided context highlights a crucial limitation of NGS for NTM diagnosis: 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' Therefore, despite a negative NGS result, the high clinical suspicion and positive AFB smears necessitate proceeding with traditional mycobacterial cultures and species identification, which remain the gold standard for NTM diagnosis and guiding specific therapy.",
    "highYieldPearl": "Rio's Take: For NTM, positive AFB smears coupled with characteristic imaging and symptoms should prompt mycobacterial cultures even if molecular tests like NGS are negative, due to the recognized limitations of current molecular methods in detecting NTM DNA abundance.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Incorrect. Empiric broad-spectrum antibiotics are unlikely to be effective against NTM, and repeating NGS, which has known sensitivity issues for NTM, is not the most definitive next step when standard cultures are available.",
      "B": "Correct. Given the strong clinical and radiological suspicion for NTM, and the positive AFB smears, mycobacterial cultures are essential for confirming the diagnosis, identifying the specific NTM species, and guiding appropriate treatment. The context explicitly states NGS may have inadequate sensitivity compared to cultures for NTM.",
      "C": "Incorrect. While a transbronchial biopsy might provide histopathological evidence, it is more invasive. With repeatedly positive AFB smears, cultures are less invasive and provide the crucial species identification needed for treatment, making it the 'most appropriate next' step before considering biopsy.",
      "D": "Incorrect. Discontinuing the NTM workup based solely on a negative NGS, especially with repeatedly positive AFB smears and a compelling clinical picture, would be a critical diagnostic error due to the known sensitivity limitations of NGS for NTM."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_386eaa43",
    "question": "A 48-year-old non-smoking male presents with a chronic, productive cough and recurrent respiratory infections over the past year. He reports no fever, night sweats, or significant weight loss. A chest CT scan reveals bilateral upper lobe bronchiectasis with associated scattered ground-glass opacities and small nodules. Sputum AFB smears are positive. Based on the radiological findings and clinical presentation, which of the following is the most consistent diagnosis?",
    "options": {
      "A": "Miliary tuberculosis",
      "B": "Nontuberculous mycobacterial (NTM) disease",
      "C": "Fungal pneumonia",
      "D": "Primary tuberculosis with lymphadenopathy"
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with chronic cough, recurrent infections, and lack of systemic symptoms like fever or weight loss, in conjunction with the specific radiological pattern of bilateral upper lobe bronchiectasis, strongly points towards nontuberculous mycobacterial (NTM) disease. The provided context states, 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' While positive AFB smears indicate a mycobacterial infection, the clinical and radiological features differentiate NTM from typical TB presentations. Upper lobe bronchiectasis, particularly in non-smokers without CF, is a classic finding in NTM, often seen with Mycobacterium avium complex.",
    "highYieldPearl": "Rio's Take: Chronic cough and recurrent infections in a non-smoking individual, especially with upper lobe bronchiectasis on CT, should raise high suspicion for NTM disease, even with positive AFB smears. This presentation often contrasts with the more acute or systemic features of active TB.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Incorrect. Miliary tuberculosis is characterized by diffuse small (miliary) nodules throughout the lung parenchyma, usually in the context of severe systemic illness. Bronchiectasis is not a typical predominant feature of miliary TB.",
      "B": "Correct. The presence of bilateral upper lobe bronchiectasis with associated ground-glass opacities and small nodules, combined with a chronic indolent course and positive AFB smears, is highly consistent with NTM pulmonary disease, as explicitly mentioned in the context.",
      "C": "Incorrect. While fungal pneumonia can cause nodules and ground-glass opacities, bronchiectasis as a primary or prominent feature, especially in the upper lobes with positive AFB, is less characteristic of typical fungal infections compared to NTM.",
      "D": "Incorrect. Primary tuberculosis often presents with parenchymal disease, lymphadenopathy, or pleural effusion. While parenchymal disease can include nodules, prominent, bilateral upper lobe bronchiectasis with a chronic, non-systemic course is not the typical presentation of primary TB. The lack of significant lymphadenopathy also argues against this."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_1f1de4ea",
    "question": "A 55-year-old male, who underwent allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia 18 months ago, presents with chronic cough, weight loss, and progressive dyspnea. He has a history of severe chronic graft-versus-host disease (GVHD) affecting the skin and gut, for which he is on high-dose corticosteroids and tacrolimus. Recent laboratory tests show persistent low-level CMV viremia. Chest CT reveals extensive bronchiectasis, multiple small nodules, and tree-in-bud opacities. Initial bacterial and fungal cultures from bronchoalveolar lavage (BAL) are negative after 72 hours. What is the most likely diagnosis, and what is the crucial diagnostic step needed?",
    "options": {
      "A": "Nontuberculous mycobacterial infection; culture of BAL for mycobacteria.",
      "B": "Active tuberculosis; Interferon-gamma release assay (IGRA) on BAL.",
      "C": "Cytomegalovirus pneumonia; Quantitative PCR for CMV DNA in BAL.",
      "D": "Cryptogenic organizing pneumonia; Surgical lung biopsy for histopathology."
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's clinical presentation, including chronic cough, weight loss, and progressive dyspnea 18 months post-HCT, coupled with specific risk factors like severe chronic GVHD and CMV viremia, strongly suggests a nontuberculous mycobacterial (NTM) infection. The text highlights that NTMs are increasingly recognized as a 'late infectious problem' in HCT recipients, with a median onset of 343 days post-HCT, and are associated with severe chronic GVHD and CMV viremia. Radiographically, bronchiectasis is explicitly mentioned as being consistent with NTM disease. Furthermore, the text indicates that molecular methods like NGS may have inadequate sensitivity compared to cultures for NTM, making mycobacterial culture from BAL the crucial diagnostic step for definitive identification and susceptibility testing.",
    "highYieldPearl": "Rio's Take: NTM infection should be high on the differential for late-onset pulmonary symptoms (beyond 1 year) in HCT recipients, especially those with chronic GVHD and CMV viremia. Bronchiectasis on imaging is a key clue, and mycobacterial culture remains the gold standard for diagnosis due to potential limitations of molecular assays.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This option accurately identifies NTM as the most likely diagnosis given the late presentation, risk factors (GVHD, CMV), and imaging (bronchiectasis) in an HCT recipient. It also correctly emphasizes the crucial role of mycobacterial culture for diagnosis, acknowledging the limitations of rapid molecular tests for NTM, as mentioned in the text.",
      "B": "Trap: While TB is a differential in immunocompromised patients, NTM is more strongly indicated by the specific constellation of late onset in HCT, chronic GVHD, and CMV viremia. IGRA is primarily used for diagnosing latent TB infection (LTBI) and not recommended for diagnosing active TB from BAL fluid, nor does it distinguish between latent and active disease. Active TB is also rare in HCT, especially late.",
      "C": "Trap: CMV viremia is noted as an *association* for NTM in HCT, not necessarily the primary cause of pneumonia with extensive bronchiectasis. While CMV PCR on BAL is a valid test for CMV pneumonia, the clinical and radiographic picture here leans more towards NTM, and treating CMV might not resolve the underlying NTM infection.",
      "D": "Trap: Cryptogenic organizing pneumonia (COP) can present with chronic symptoms and nodular opacities in HCT patients. However, the explicit mention of bronchiectasis, combined with the specific risk factors for NTM (GVHD, CMV, late presentation), makes NTM a more specific and likely infectious etiology to rule out first with less invasive methods. Surgical lung biopsy is a more invasive step, usually pursued after non-invasive diagnostics have failed."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_442bf2b9",
    "question": "A 62-year-old female with a history of bilateral upper lobe bronchiectasis and recurrent respiratory infections presents with worsening cough, fevers, and weight loss over 6 months. She has no known immunocompromise. Due to the chronic nature of her symptoms, a bronchoscopy with bronchoalveolar lavage (BAL) was performed. A comprehensive molecular panel on the BAL, including next-generation sequencing (NGS), reported 'low-level detection of Mycobacterium avium complex DNA, below the threshold of reliable quantification.' Routine bacterial and fungal cultures were negative. What is the most appropriate next step in her management?",
    "options": {
      "A": "Commence empiric therapy with clarithromycin, ethambutol, and rifampin due to high clinical suspicion.",
      "B": "Request specific mycobacterial culture and AFB smear from the already collected BAL sample.",
      "C": "Consider the NGS result as evidence of colonization and investigate for other causes of chronic bronchiectasis exacerbation.",
      "D": "Obtain a CT-guided lung biopsy to confirm granulomatous inflammation and perform tissue culture for mycobacteria."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with chronic respiratory symptoms, weight loss, and existing bronchiectasis is highly suggestive of NTM disease. The text explicitly states that 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This highlights that a 'low-level detection' on NGS for NTM is an inconclusive finding and does not rule out active infection. Given the clinical suspicion and the known limitations of molecular diagnostics for NTM, obtaining a definitive mycobacterial culture from the BAL sample (which should have been collected and preserved) is the most appropriate and crucial next step to confirm the diagnosis, speciate the NTM, and perform susceptibility testing before initiating potentially prolonged and complex therapy.",
    "highYieldPearl": "Rio's Take: Low-level NTM DNA detection by molecular methods like NGS, especially in the setting of suggestive clinical and radiographic findings (e.g., bronchiectasis, chronic symptoms), should not be dismissed. Mycobacterial culture remains essential for definitive diagnosis, speciation, and guiding therapy due to the documented lower sensitivity of molecular assays for NTM.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "Trap: Initiating empiric NTM therapy without definitive culture confirmation and susceptibility testing is generally not recommended. NTM treatment regimens are complex, prolonged, and drug toxicities are common. Confirmation of species and susceptibility guided therapy is crucial.",
      "B": "Correct: This directly addresses the diagnostic challenge highlighted in the text, emphasizing that NGS may have inadequate sensitivity for NTM. Given the strong clinical suspicion (chronic symptoms, bronchiectasis) and the presence of NTM DNA (even if low-level), pursuing definitive mycobacterial culture is the most logical and necessary next step for diagnosis.",
      "C": "Trap: While distinguishing NTM colonization from infection can be challenging, the patient's symptoms (worsening cough, fevers, weight loss) and radiographic findings (bronchiectasis, which is consistent with NTM) suggest active disease rather than mere colonization. Dismissing the NTM DNA finding prematurely, especially given the known limitations of molecular tests for NTM, would be inappropriate.",
      "D": "Trap: A CT-guided lung biopsy is a more invasive procedure. While it might be necessary if less invasive methods fail, the first step should be to fully utilize the already obtained BAL sample for definitive mycobacterial culture, which is less risky and directly addresses the diagnostic gap."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_3cf9226e",
    "question": "A 48-year-old male recipient of a lung transplant 2 years ago, maintained on tacrolimus and mycophenolate mofetil, presents with a persistent productive cough, fatigue, and new-onset weight loss. A chest CT scan shows new multifocal bronchiectasis and tree-in-bud opacities in the right middle lobe. Bronchoscopy with BAL culture later grows *Mycobacterium kansasii*. The isolate is susceptible to rifampin, ethambutol, and macrolides. Which of the following considerations is paramount in initiating appropriate antimicrobial therapy for this patient?",
    "options": {
      "A": "Rifampin is absolutely contraindicated due to the risk of acute allograft rejection secondary to reduced tacrolimus levels.",
      "B": "A standard regimen of isoniazid, rifampin, pyrazinamide, and ethambutol should be initiated, with close monitoring for hepatotoxicity.",
      "C": "If rifampin is chosen, tacrolimus dose will require significant upward adjustment and frequent therapeutic drug monitoring.",
      "D": "Macrolide monotherapy is the preferred initial approach for *M. kansasii* in lung transplant recipients to avoid drug interactions."
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient has a confirmed NTM infection (*Mycobacterium kansasii*) in the setting of a lung transplant, where he is maintained on tacrolimus. The text explicitly warns about the use of rifampin: 'The use of rifampin can be problematic due to the increased risk of hepatotoxicity and the induction of cytochrome P450 isoenzymes, which can reduce serum concentrations of several immunosuppressants and azole antifungals, potentially leading to allograft rejection and infection.' It further states: 'During rifampin treatment, doses of the immunosuppressants cyclosporine, tacrolimus, and sirolimus must be increased and signs of rejection closely monitored.' Therefore, if rifampin is chosen (which is a standard component of *M. kansasii* therapy), significant dose adjustments of tacrolimus and vigilant monitoring of its levels are paramount to prevent allograft rejection while ensuring adequate NTM treatment. Rifabutin may be considered as a less potent inducer of P450 if the interaction is too difficult to manage.",
    "highYieldPearl": "Rio's Take: When treating NTM (or TB) in solid-organ transplant recipients on calcineurin inhibitors (e.g., tacrolimus, cyclosporine), rifampin's potent cytochrome P450 induction necessitates substantial upward dose adjustments and meticulous therapeutic drug monitoring of the immunosuppressant to prevent allograft rejection. Rifabutin is a less potent inducer and is often preferred if available and effective.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "Trap: 'Absolutely contraindicated' is too strong. While the interaction is severe, rifampin *can* be used with careful management, including significant dose adjustments and close monitoring of tacrolimus levels, or by substituting rifabutin. It is not an absolute contraindication but requires vigilant management.",
      "B": "Trap: This option incorrectly suggests standard TB quadruple therapy. *Mycobacterium kansasii* is an NTM, not *M. tuberculosis*. While rifampin and ethambutol are often part of *M. kansasii* regimens, isoniazid and pyrazinamide are typically not used for *M. kansasii*, distinguishing NTM treatment from TB. This tests the knowledge of specific NTM treatment principles versus standard TB regimens.",
      "C": "Correct: This statement directly reflects the critical information provided in the text regarding rifampin's potent P450 induction, leading to reduced immunosuppressant levels, and the necessity for increased doses and close monitoring of drugs like tacrolimus to prevent allograft rejection.",
      "D": "Trap: Monotherapy for *Mycobacterium kansasii* (or most NTMs) is not recommended due to a high risk of developing drug resistance and treatment failure. Multi-drug regimens are standard for NTM infections to ensure efficacy and prevent resistance, even in transplant recipients."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_927d727a",
    "question": "A 45-year-old male who underwent allogeneic hematopoietic cell transplantation (HCT) 1 year ago presents with chronic cough and progressive shortness of breath. He has a history of severe chronic graft-versus-host disease (GVHD) and recently had a positive CMV viremia. Chest CT scan reveals extensive bronchiectasis. Which of the following mycobacterial infections is most strongly suggested by this clinical picture?",
    "options": {
      "A": "Nontuberculous Mycobacteria (NTM)",
      "B": "Active tuberculosis (TB)",
      "C": "Latent tuberculosis infection (LTBI) reactivation",
      "D": "Disseminated Mycobacterium bovis infection"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's clinical presentation aligns perfectly with the characteristics of NTM pulmonary infection in HCT recipients described in the text. NTMs are increasingly recognized as a late infectious problem in HCT, with a median onset of lung disease at 343 days post-HCT (1 year in this vignette). Key risk factors include severe chronic GVHD and cytomegalovirus (CMV) viremia, both present in this patient. Furthermore, the text specifically states that 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.'",
    "highYieldPearl": "Rio's Take: In HCT recipients, think NTM for late-onset pulmonary disease, especially with chronic GVHD, CMV viremia, and radiographic bronchiectasis.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This option is correct as it directly matches the clinical features (late onset post-HCT, chronic GVHD, CMV viremia, bronchiectasis) described for NTM in the provided text.",
      "B": "Active TB is rare post-HCT and the specific combination of late onset (1 year post), chronic GVHD, CMV viremia, and extensive bronchiectasis points more strongly to NTM as per the text. While TB can cause bronchiectasis, the entire clinical picture is more indicative of NTM based on the provided context.",
      "C": "LTBI is an infection state, not an active disease. Reactivation would present as active TB, which is less likely given the specific risk factors and timing for NTM highlighted in the text.",
      "D": "*Mycobacterium bovis* is a specific type of mycobacterium, but the scenario does not provide information to suggest this specific pathogen. It serves as a general mycobacterial distractor."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_4798e5b8",
    "question": "A 55-year-old male, 8 months post-allogeneic hematopoietic cell transplantation (HCT), presents with persistent cough and fatigue. Screening for tuberculosis was negative pre-transplant. Given the potential for nontuberculous mycobacterial (NTM) infection in HCT recipients, which of the following statements is most accurate regarding NTM epidemiology post-HCT?",
    "options": {
      "A": "NTM pulmonary infections are typically a late complication, often presenting after 300 days post-HCT.",
      "B": "NTM infections are primarily seen in the early post-transplant period, typically within the first 100 days.",
      "C": "The incidence of NTM in HCT recipients is comparable to that in the general population.",
      "D": "NTM infections are almost exclusively limited to central catheter-associated and skin infections in HCT recipients."
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The text explicitly states: 'nontuberculous mycobacterial (NTM) pulmonary infections are uncommon, particularly in the early post‑transplant period, but NTMs are increasingly recognized as a late infectious problem.' It further specifies that 'The vast majority of cases (93 %) presented with lung disease at a median time after HCT of 343 days.' This directly supports option A.",
    "highYieldPearl": "Rio's Take: NTM is a late-onset pulmonary issue in HCT, occurring at a higher rate than the general population, not an early or exclusively non-pulmonary one.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This statement is accurate, as the text describes NTM pulmonary infections as a 'late infectious problem' with a median onset of 343 days post-HCT.",
      "B": "This is incorrect. The text states NTM pulmonary infections are 'uncommon, particularly in the early post-transplant period.'",
      "C": "This is incorrect. The text reports NTMs in 2.7% of allogeneic HCT recipients, a 'markedly higher rate than in the general population.'",
      "D": "This is incorrect. While NTMs 'can also be seen in the early post‑transplant period as central catheter‑associated and skin infections,' the text clarifies that 'The vast majority of cases (93 %) presented with lung disease,' indicating pulmonary disease is the predominant manifestation, not just skin or catheter infections."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_b04c599a",
    "question": "A 62-year-old female, 18 months post-autologous HCT, presents with a persistent cough and occasional hemoptysis. She has no history of chronic GVHD or recent CMV viremia. Chest CT scan is performed to investigate her symptoms. Which of the following radiological findings, if present, would most strongly suggest a nontuberculous mycobacterial (NTM) pulmonary infection?",
    "options": {
      "A": "Diffuse miliary nodules",
      "B": "Solitary cavitary lesion in the lung apex",
      "C": "New onset pleural effusion with hilar lymphadenopathy",
      "D": "Bronchiectasis"
    },
    "correctAnswer": "D",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The text directly states: 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' This makes bronchiectasis the most specific radiological finding for NTM among the options provided, based on the given context. Other options are generally more associated with primary or reactivation tuberculosis.",
    "highYieldPearl": "Rio's Take: When considering NTM pulmonary disease, especially in the context of HCT, bronchiectasis on CT scan is a key radiological clue.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "Diffuse miliary nodules are characteristic of miliary tuberculosis, although other infections or malignancies can also present similarly. The text mentions 'miliary disease' as a possible presentation of primary TB.",
      "B": "A solitary cavitary lesion, particularly in the lung apex, is a classic presentation of post-primary (reactivation) tuberculosis. The text mentions 'parenchymal disease with or without associated cavitation can mimic a variety of bacterial or fungal pneumonias' or TB.",
      "C": "Pleural effusion and hilar lymphadenopathy are common radiological findings associated with primary tuberculosis infection.",
      "D": "This is the correct answer. The text explicitly links 'Bronchiectasis' with 'nontuberculous mycobacterial (NTM) disease,' making it the most direct and specific indicator among the choices for NTM."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_811be770",
    "question": "A 45-year-old male who underwent allogeneic hematopoietic cell transplantation 1 year ago for acute myeloid leukemia presents with a 2-month history of productive cough, dyspnea, and weight loss. He has a history of severe chronic graft-versus-host disease (cGVHD) affecting the skin and liver. Chest CT scan reveals multifocal bronchiectasis with associated tree-in-bud opacities. Sputum acid-fast bacilli (AFB) stain is positive.",
    "options": {
      "A": "Nontuberculous mycobacterial (NTM) pulmonary infection",
      "B": "Reactivation of latent tuberculosis infection (LTBI)",
      "C": "Donor-derived active tuberculosis",
      "D": "Early post-transplant NTM central catheter-associated infection"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation 1 year post-allogeneic HCT, with severe chronic GVHD, and pulmonary involvement (bronchiectasis, tree-in-bud opacities) strongly points towards NTM. The provided text states that NTM is increasingly recognized as a late infectious problem in HCT, with 93% presenting with lung disease at a median of 343 days post-HCT, and is associated with severe chronic GVHD. Bronchiectasis is also specifically mentioned as a radiographic finding consistent with NTM disease.",
    "highYieldPearl": "NTM pulmonary infections are a significant late complication in HCT recipients, particularly those with chronic GVHD, often manifesting with bronchiectasis.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This option is directly supported by the patient's timeline (late post-HCT), risk factors (severe cGVHD), and radiographic findings (bronchiectasis) mentioned in the context.",
      "B": "While reactivation of LTBI is possible in immunocompromised patients, active TB is stated to be rare in HCT (0.23–0.79%), even with untreated LTBI. The combination of late onset in HCT with chronic GVHD and typical NTM radiographic patterns makes NTM more consistent based on the provided context.",
      "C": "Donor-derived mycobacterial infections have been reported in solid-organ transplantation (SOT) but are not highlighted as a common issue for TB in HCT, and less likely given the 1-year post-transplant timeline for active disease presentation.",
      "D": "The vignette describes a pulmonary infection 1 year post-transplant, not an early (<343 days) catheter-associated or skin infection. This option contradicts both the timeline and the primary site of infection mentioned in the text for the majority of NTM cases."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_7e5bb0b6",
    "question": "A 60-year-old female with known non-cystic fibrosis bronchiectasis presents with worsening cough and dyspnea. Sputum samples are sent for mycobacterial culture and also for next-generation sequencing (NGS) to rapidly identify potential pathogens. After several weeks, the mycobacterial culture grows *Mycobacterium avium complex*. The NGS report, however, showed a very low abundance of *Mycobacterium* species DNA, initially leading clinicians to question its pathogenicity.",
    "options": {
      "A": "NTM DNA typically has low abundance, potentially leading to inadequate sensitivity of NGS compared to culture.",
      "B": "NGS is routinely inhibited by host DNA in sputum samples, leading to false negatives for NTM.",
      "C": "The specific NGS platform used was optimized for bacterial pneumonia, not mycobacterial species.",
      "D": "*Mycobacterium avium complex* is a known contaminant in sputum samples, explaining the low NGS signal."
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided text explicitly states regarding NTM: 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This directly explains the discrepancy between the positive culture and the low abundance detected by NGS in the vignette.",
    "highYieldPearl": "While powerful, NGS may have limitations in detecting NTM due to characteristically low organism burden and DNA abundance, making traditional culture methods often more sensitive for NTM.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This statement is a direct recall from the provided context regarding NTM diagnostics and NGS limitations.",
      "B": "While host DNA can be a challenge in NGS, the text specifically attributes the NTM detection discrepancy to low NTM DNA abundance, not general inhibition by host DNA.",
      "C": "This is a plausible technical issue for NGS in general, but the provided text gives a more fundamental and specific reason related to NTM characteristics (low DNA abundance) rather than a general platform optimization problem.",
      "D": "While NTM can be colonizers, the vignette states that *Mycobacterium avium complex* was identified by culture, implying a potential infection. The question asks about the diagnostic discrepancy based on the *provided context*, which highlights low DNA abundance as a characteristic for pathogenic NTM detection by NGS, not merely contamination."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_2be057f1",
    "question": "A 55-year-old male with a history of severe chronic graft-versus-host disease (cGVHD) following an allogeneic hematopoietic stem cell transplant 2 years prior, presents with a persistent cough and new exertional dyspnea. He denies fever or hemoptysis. His baseline chest X-ray 6 months ago was normal. A recent chest CT scan reveals new bilateral upper lobe infiltrates with cavitation and bronchiectasis.",
    "options": {
      "A": "Pulmonary disease is the most common presentation of NTM infection in HCT recipients, typically occurring as a late complication.",
      "B": "NTM infections are primarily associated with central catheter-related bloodstream infections in HCT recipients.",
      "C": "The incidence of NTM infection in HCT recipients is similar to that of the general population.",
      "D": "Early post-transplant NTM infections are more common than late-onset infections in HCT recipients."
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The text states: 'The vast majority of cases (93%) presented with lung disease at a median time after HCT of 343 days.' It also mentions 'NTMs are increasingly recognized as a late infectious problem' in HCT. This directly supports option A, aligning with the patient's 2-year post-transplant history, cGVHD, and pulmonary findings (infiltrates, cavitation, bronchiectasis).",
    "highYieldPearl": "NTM pulmonary infections are a significant late complication in HCT recipients, especially in the context of chronic GVHD.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This statement is directly supported by the provided text regarding the most common presentation and timeline of NTM infections in HCT recipients.",
      "B": "The text mentions that central catheter-associated and skin infections can be seen early post-transplant, but explicitly states that 'the vast majority of cases (93%) presented with lung disease'. Therefore, pulmonary disease, not catheter-related infection, is the primary association.",
      "C": "The text states that NTMs were identified in HCT recipients in '2.7%, a markedly higher rate than in the general population.' This option is directly contradicted.",
      "D": "The text clearly states that NTMs are 'uncommon, particularly in the early post-transplant period... but NTMs are increasingly recognized as a late infectious problem.' This option is directly contradicted."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_d1aad0e5",
    "question": "A 45-year-old male, who underwent allogeneic hematopoietic cell transplantation (HCT) 10 months ago for acute myeloid leukemia, presents with persistent cough, low-grade fever, and dyspnea. He has a history of severe chronic graft-versus-host disease (GVHD) affecting the skin and liver, for which he is on immunosuppression. A CT scan of the chest reveals new bilateral upper lobe nodular opacities with some cavitation and bronchiectasis. Sputum cultures are pending. Based on his clinical context, which of the following statements regarding Nontuberculous Mycobacteria (NTM) infection in HCT recipients is most accurate?",
    "options": {
      "A": "NTM infections in HCT recipients are typically seen in the early post-transplant period, usually within the first 3 months.",
      "B": "The prevalence of NTM infection in allogeneic HCT recipients is similar to that of the general population.",
      "C": "Lung disease is the most common presentation of NTM infection in HCT recipients.",
      "D": "NTM infections in HCT recipients are rarely associated with chronic graft-versus-host disease (GVHD)."
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided text explicitly states that NTMs are 'increasingly recognized as a late infectious problem' in HCT recipients, with a median time after HCT of 343 days. It also highlights that the 'vast majority of cases (93%) presented with lung disease' and that NTM was 'associated with severe chronic GVHD'. Furthermore, the prevalence in a cohort of 1,047 allogeneic HCT recipients was 2.7%, described as 'a markedly higher rate than in the general population'. Therefore, lung disease being the most common presentation is the most accurate statement.",
    "highYieldPearl": "Rio's Take: NTM infection post-HCT is typically a late complication, frequently manifesting as pulmonary disease, and is strongly linked to chronic GVHD, occurring at a higher rate than in the general population.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This is incorrect. The text states NTM is 'increasingly recognized as a late infectious problem' with a median onset of 343 days post-HCT, not early post-transplant.",
      "B": "This is incorrect. The text indicates a prevalence of 2.7% in HCT recipients, which is described as 'a markedly higher rate than in the general population'.",
      "C": "This is the correct answer. The text states, 'The vast majority of cases (93%) presented with lung disease'.",
      "D": "This is incorrect. The text directly states that NTM 'was associated with severe chronic GVHD'."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_7ceab577",
    "question": "A 60-year-old female with a history of recurrent pulmonary infections and known bronchiectasis undergoes a diagnostic bronchoscopy for persistent cough and new infiltrates on chest imaging. Standard bacterial cultures are negative, and PCR for common respiratory viruses is also negative. Given the suspicion for Nontuberculous Mycobacteria (NTM) infection, a next-generation sequencing (NGS) analysis of her bronchoalveolar lavage fluid is performed. Based on the current understanding of NTM and NGS as presented in the context, which of the following is the most likely finding?",
    "options": {
      "A": "NGS analysis is expected to show high abundance of NTM DNA, making it highly sensitive for diagnosis.",
      "B": "NTM DNA, if present, is likely to have low abundance, potentially near or below the limit of detection for NGS.",
      "C": "NGS profiles for NTM infections are ecologically similar to other bacterial pneumonias.",
      "D": "NGS is superior to traditional mycobacterial cultures for NTM detection due to its rapid turnaround time."
    },
    "correctAnswer": "B",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided text explicitly discusses NTM infection in the context of NGS, stating: 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This directly supports option B. It also notes that the microbial profiles are 'distinct from other bacterial infections'.",
    "highYieldPearl": "Rio's Take: While NGS offers insights into microbial communities, its utility for NTM diagnosis is limited by the inherently low abundance of NTM DNA, making traditional cultures often more sensitive.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This is incorrect. The text states NTM DNA has 'low abundance' and NGS 'may have inadequate sensitivity', directly contradicting high abundance and high sensitivity.",
      "B": "This is the correct answer. The text states, 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.'",
      "C": "This is incorrect. The text states that NTM microbial profiles 'disclosed an ecologic profile distinct from other bacterial infections'.",
      "D": "This is incorrect. While NGS can be rapid, the text suggests it 'may have inadequate sensitivity compared to cultures for NTM', implying it is not superior for NTM detection despite potential speed advantages."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_63097d74",
    "question": "A 55-year-old non-smoker presents with a chronic productive cough, progressive dyspnea, and occasional hemoptysis. Chest CT scan reveals multifocal bronchiectasis predominantly in the middle lobe and lingula, with associated centrilobular nodules. There is no evidence of hilar lymphadenopathy, pleural effusion, or miliary pattern. Sputum acid-fast bacilli (AFB) smears are negative, but cultures are pending. Considering the radiographic findings described in the provided text, which of the following mycobacterial infections is most consistent with this imaging pattern?",
    "options": {
      "A": "Miliary tuberculosis (TB).",
      "B": "Primary pulmonary tuberculosis (TB) with hilar lymphadenopathy.",
      "C": "Latent tuberculosis infection (LTBI).",
      "D": "Nontuberculous Mycobacterial (NTM) disease."
    },
    "correctAnswer": "D",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided text explicitly states, 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' The clinical vignette describes prominent bronchiectasis, which aligns perfectly with this statement. Other options like miliary TB, primary TB with hilar lymphadenopathy, or LTBI do not fit the described radiographic pattern or the definition of LTBI as per the text's emphasis.",
    "highYieldPearl": "Rio's Take: When you see bronchiectasis, especially in the setting of chronic cough and negative routine cultures, think NTM. The middle lobe and lingula are common sites for NTM-associated bronchiectasis.",
    "examStyle": "NEET-SS",
    "difficulty": "easy",
    "trapAnalysis": {
      "A": "This is inconsistent. Miliary TB is characterized by diffuse small (millet seed-sized) nodules throughout the lung parenchyma, which is distinct from the described multifocal bronchiectasis.",
      "B": "This is inconsistent. While primary TB can cause parenchymal disease, lymphadenopathy is often a prominent feature, and the vignette explicitly states 'no hilar lymphadenopathy'. Also, the primary finding is bronchiectasis, which the text specifically links to NTM.",
      "C": "This is inconsistent. Latent tuberculosis infection (LTBI) is an asymptomatic state diagnosed by TST or IGRA and does not present with active radiographic findings such as bronchiectasis or nodular opacities.",
      "D": "This is the correct answer. The text directly states that 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease'. The described CT findings of bronchiectasis and centrilobular nodules are classic for NTM pulmonary disease."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_2a99b67a",
    "question": "A 45-year-old male, 1.5 years post-allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia, presents with progressive cough, dyspnea, and recurrent low-grade fevers. He has a history of severe chronic graft-versus-host disease (GVHD) affecting the skin and gut, and had a treated episode of CMV viremia 6 months ago. High-resolution CT (HRCT) of the chest shows widespread bronchiolectasis, tree-in-bud opacities, and multiple small nodules, predominantly in the middle lobe and lingula. Sputum acid-fast bacilli (AFB) stain is positive. Considering his clinical history and radiological findings, which of the following is the most likely causative organism?",
    "options": {
      "A": "Nontuberculous Mycobacteria (NTM)",
      "B": "Cytomegalovirus (CMV)",
      "C": "Aspergillus fumigatus",
      "D": "Mycobacterium tuberculosis"
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The patient's presentation with chronic respiratory symptoms, late onset (1.5 years post-HCT), history of severe chronic GVHD, and prior CMV viremia are all strongly associated with Nontuberculous Mycobacterial (NTM) pulmonary infection, as per the provided context. The text states that NTMs are increasingly recognized as a late infectious problem in HCT recipients, with 93% presenting with lung disease at a median of 343 days post-HCT, and are associated with severe chronic GVHD and CMV viremia. The HRCT findings of bronchiolectasis and tree-in-bud opacities are also classic radiological features of NTM pulmonary disease. While sputum AFB stain positivity can be seen in both NTM and M. tuberculosis, the clinical context heavily favors NTM.",
    "highYieldPearl": "Rio's Take: NTM pulmonary infections in HCT recipients are typically late-onset, associated with chronic GVHD and CMV viremia, and commonly present with bronchiectasis and tree-in-bud opacities on HRCT.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "This option is consistent with all key aspects of the vignette: late post-HCT, chronic GVHD, prior CMV, and characteristic HRCT findings (bronchiectasis, nodules/tree-in-bud typical for NTM).",
      "B": "CMV viremia is identified as a risk factor/association for NTM in the context, not typically the direct cause of this specific bronchiectatic pattern in late post-HCT. While CMV can cause pneumonitis, the described chronic bronchiectatic pattern is less typical for CMV itself.",
      "C": "Aspergillus fumigatus is a common fungal pathogen in HCT recipients, particularly with GVHD. However, the HRCT findings of widespread bronchiolectasis and tree-in-bud are more characteristic of NTM than typical aspergillosis (which often presents as nodules, cavitations, or invasive disease). The positive AFB stain also points away from fungal infection.",
      "D": "Mycobacterium tuberculosis (TB) is less common post-HCT in low-endemicity regions, and while it can cause cavitary disease, the prominence of bronchiolectasis with tree-in-bud in this specific clinical context (late post-HCT, severe chronic GVHD) makes NTM a more likely diagnosis based on the provided context, which highlights NTM as a 'late infectious problem' with specific associations."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_7c305509",
    "question": "A 62-year-old female with a history of recurrent respiratory infections and known bronchiectasis is suspected of having Nontuberculous Mycobacterial (NTM) lung disease. A bronchoalveolar lavage (BAL) sample is obtained. The microbiology laboratory reports that a novel Next-Generation Sequencing (NGS) assay performed on the BAL fluid detected NTM DNA, but the abundance was very low, near the assay's limit of detection. Clinically, suspicion for NTM remains high. Which of the following is the most appropriate next step to confirm the diagnosis?",
    "options": {
      "A": "Initiate empiric NTM multi-drug therapy immediately.",
      "B": "Repeat the NGS assay using a different molecular panel.",
      "C": "Perform mycobacterial culture on the BAL fluid.",
      "D": "Obtain a transthoracic lung biopsy for histopathological and microbiological examination."
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided context explicitly states regarding NTM: 'The causative NTM DNA has low abundance, near or below the limit of detection of dedicated molecular methods, suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.' This indicates that despite low abundance detection by NGS, culture remains a more sensitive method for definitive diagnosis. Therefore, performing a mycobacterial culture on the BAL fluid is the most appropriate next step to confirm the diagnosis when NGS yields equivocal results.",
    "highYieldPearl": "Rio's Take: For NTM diagnosis, traditional mycobacterial culture often demonstrates superior sensitivity compared to NGS methods due to the typically low abundance of NTM DNA in samples.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Initiating empiric multi-drug therapy without definitive microbiological confirmation is generally not recommended for NTM, given the complexity, duration, and potential side effects of treatment, and the importance of species identification for guiding therapy.",
      "B": "Repeating an NGS assay, even with a different panel, is unlikely to overcome the inherent limitation of NGS sensitivity for NTM as described in the context, where low NTM DNA abundance is a known issue for these molecular methods.",
      "C": "This is the correct answer. The text directly states that NGS may have 'inadequate sensitivity compared to cultures for NTM,' making culture the more sensitive and definitive diagnostic method in this scenario.",
      "D": "A transthoracic lung biopsy is an invasive procedure and is typically reserved for cases where less invasive methods (like BAL culture) are non-diagnostic, or when there is a need to rule out other pathologies not amenable to BAL. It carries higher risks compared to simply culturing the already obtained BAL fluid."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_c8af39af",
    "question": "A 38-year-old male with chronic obstructive pulmonary disease (COPD) and a 15-year history of smoking presents with persistent productive cough, weight loss, and fatigue. His chest X-ray shows apical fibrocavitary lesions. Sputum samples are sent for AFB smear and culture. While awaiting culture results, the clinician is considering the differential diagnosis between Mycobacterium tuberculosis (TB) and Nontuberculous Mycobacteria (NTM). Which of the following radiological patterns, if exclusively present, would most strongly favor NTM disease over active TB in this patient?",
    "options": {
      "A": "Multiple discrete nodules with ground-glass halos",
      "B": "Extensive hilar and mediastinal lymphadenopathy",
      "C": "Bilateral upper lobe bronchiectasis with associated tree-in-bud opacities",
      "D": "Miliary infiltration throughout both lung fields"
    },
    "correctAnswer": "C",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "The provided context explicitly states, 'Bronchiectasis may be consistent with nontuberculous mycobacterial (NTM) disease.' In contrast, the context lists 'parenchymal disease (with or without associated cavitation), lymphadenopathy, pleural effusion, or miliary disease' as findings consistent with primary TB infection. While TB can cause bronchiectasis, the phrasing 'Bronchiectasis may be consistent with NTM disease' specifically highlights this as a key radiological feature of NTM. Given the question asks what would *most strongly favor* NTM over TB, bilateral upper lobe bronchiectasis with tree-in-bud (a common sign of endobronchial spread or active infection within dilated airways) is the most discriminatory option based on the provided text.",
    "highYieldPearl": "Rio's Take: While TB can cause varied radiological patterns, bronchiectasis, especially with tree-in-bud opacities, is a particularly characteristic feature often associated with NTM pulmonary disease.",
    "examStyle": "NEET-SS",
    "difficulty": "moderate",
    "trapAnalysis": {
      "A": "Nodules with or without concomitant ground glass are mentioned as consistent with 'other infections or with malignancy,' but not specifically highlighted as unique to NTM over TB in the provided text. TB can also present with nodules.",
      "B": "Extensive hilar and mediastinal lymphadenopathy is specifically mentioned as a presentation of 'primary TB infection' in the context, making it a feature of TB, not one that favors NTM.",
      "C": "This is the correct answer. The text directly links 'Bronchiectasis' to 'nontuberculous mycobacterial (NTM) disease,' making it the most specific differentiating radiological finding mentioned for NTM.",
      "D": "Miliary disease is explicitly listed as a potential presentation of 'primary TB infection' in the context, making it a feature of TB, not one that favors NTM."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "id": "rag_asthma_diagnosis_0cdb5ab8",
    "question": "A 52-year-old male, 18 months post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia, presents with a 4-month history of progressive cough productive of mucoid sputum, dyspnea on exertion, and a 5 kg weight loss. His post-transplant course was complicated by chronic graft-versus-host disease affecting the skin and gut, and a treated cytomegalovirus viremia 8 months prior. Chest computed tomography reveals bilateral upper lobe bronchiectasis with multiple small nodules and tree-in-bud opacities. Three consecutive sputum smears for Acid-Fast Bacilli (AFB) were negative, and initial routine bacterial and fungal cultures of sputum yielded no significant growth. Which of the following is the *most appropriate immediate next diagnostic step*?",
    "options": {
      "A": "Collect additional sputum samples for mycobacterial culture and speciation.",
      "B": "Proceed with bronchoscopy and bronchoalveolar lavage (BAL) for targeted next-generation sequencing (NGS) and cytology.",
      "C": "Initiate empiric broad-spectrum antimicrobial therapy, including agents effective against atypical bacterial pathogens.",
      "D": "Perform a transthoracic lung biopsy of the affected upper lobe for histopathology and pan-fungal/bacterial cultures."
    },
    "correctAnswer": "A",
    "topic": "Nontuberculous Mycobacteria (NTM)",
    "deepDiveExplanation": "This patient's clinical presentation (chronic cough, weight loss, progressive dyspnea), history (late post-allogeneic HCT, chronic GVHD, previous CMV viremia – all identified in the context as risk factors for NTM), and characteristic CT findings (bilateral upper lobe bronchiectasis, tree-in-bud opacities) are highly suggestive of nontuberculous mycobacterial (NTM) pulmonary disease. The provided text highlights that NTM is an increasingly recognized late infectious problem in HCT recipients, particularly associated with severe chronic GVHD and CMV viremia. While initial AFB smears were negative, NTM has a low bacillary burden, and smears are often insensitive. The cornerstone of NTM diagnosis remains mycobacterial culture. The text explicitly states, “The causative NTM DNA has low abundance... suggesting that NGS approaches may have inadequate sensitivity compared to cultures for NTM.” Therefore, the most appropriate immediate next step is to obtain additional sputum samples for dedicated mycobacterial culture, which allows for isolation, identification, and susceptibility testing of the specific NTM species. The IDSA guidelines for NTM diagnosis typically require at least two positive sputum cultures with the same NTM species to confirm pulmonary NTM disease in symptomatic patients with compatible radiology.",
    "highYieldPearl": "Rio's Take: In immunocompromised patients, especially post-HCT with chronic GVHD, and characteristic radiographic features like bronchiectasis and tree-in-bud opacities, NTM pulmonary disease should be a primary differential. Despite negative AFB smears, *repeated dedicated mycobacterial cultures* are the gold standard for NTM diagnosis and often more sensitive than molecular methods like NGS for initial detection from respiratory samples.",
    "examStyle": "NEET-SS",
    "difficulty": "difficult",
    "trapAnalysis": {
      "A": "This is the correct answer. The vignette strongly points to NTM. The provided text directly supports that NTM culture is more sensitive than NGS. Obtaining *additional* samples increases diagnostic yield, especially when initial smears are negative, and is the least invasive yet effective first step towards confirming this highly suspected diagnosis.",
      "B": "This is a plausible but incorrect option and a significant trap. While BAL is a valid diagnostic tool, it's more invasive than sputum collection. More importantly, the provided text explicitly states that 'NGS approaches may have inadequate sensitivity compared to cultures for NTM' due to low NTM DNA abundance. Therefore, relying on NGS from BAL as the *immediate next* diagnostic step is suboptimal given this specific limitation for NTM and the availability of less invasive, more sensitive culture methods.",
      "C": "This is incorrect. While the patient is symptomatic, NTM treatment is prolonged, specific, and involves multiple agents tailored to the species and susceptibility. Empiric broad-spectrum therapy without a confirmed diagnosis in this chronic, progressive context would delay appropriate NTM-specific therapy, contribute to antibiotic resistance, and may not effectively cover the specific NTM strain. NTM are not typically targeted by standard 'atypical bacterial pathogen' regimens (e.g., macrolides for Mycoplasma, Chlamydia).",
      "D": "This is a highly invasive procedure. While it can provide definitive diagnosis (histopathology for granulomas, culture), it is typically reserved for situations where less invasive methods (sputum, BAL) have failed, or when there is a strong suspicion of malignancy or other severe interstitial lung disease that necessitates tissue diagnosis. Given that dedicated NTM cultures from sputum have not yet been adequately performed, this step is premature and excessively invasive as the *immediate next* action."
    },
    "sourceLocation": {
      "bookName": "69.ENDOBRONCHIAL TB (1)",
      "chapter": "Bronchoscopic classification of Endobronchial Tuberculosis",
      "section": null,
      "pageNumber": 7
    },
    "bookId": "69.ENDOBRONCHIAL TB (1)",
    "chunkId": "69.ENDOBRONCHIAL TB_OCR_Complete (1)_chunk_002",
    "generatedAt": 1767060988486,
    "timesAttempted": 0,
    "correctAttempts": 0,
    "isBundled": true
  },
  {
    "question": "What percentage increase in FEV1 and absolute change is diagnostic of asthma reversibility?",
    "options": {
      "A": "10% and 100mL",
      "B": "12% and 200mL",
      "C": "15% and 300mL",
      "D": "20% and 400mL"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Bronchodilator reversibility is a key diagnostic feature of asthma. A significant response is typically defined as an increase in FEV1 of >12% from baseline AND an absolute increase of >200 mL after administration of a short-acting bronchodilator (e.g., 400 mcg salbutamol). This criterion helps differentiate asthma from other obstructive lung diseases like COPD.",
    "highYieldPearl": "Reversibility: >12% and >200mL increase in FEV1 post-bronchodilator.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Students might confuse the percentage with the absolute value, or recall only one of the two criteria. Both must be met for a positive test.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_87fchqai"
  },
  {
    "question": "What is the PC20 threshold for diagnosing bronchial hyperresponsiveness to methacholine?",
    "options": {
      "A": "<1 mg/mL",
      "B": "<4 mg/mL",
      "C": "<8 mg/mL",
      "D": "<16 mg/mL"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "A methacholine challenge test assesses bronchial hyperresponsiveness (BHR), a hallmark of asthma. A positive test is defined as a fall in FEV1 of 20% or more from baseline (PC20) at a methacholine concentration of 8 mg/mL or less. While some guidelines may consider up to 16 mg/mL, <8 mg/mL is a more definitive and commonly accepted threshold for clinical significance.",
    "highYieldPearl": "Methacholine PC20 < 8 mg/mL indicates bronchial hyperresponsiveness.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "The exact PC20 value can vary slightly between guidelines, but <8 mg/mL is the most common and robust answer. Distracting options might include higher values which indicate less hyperresponsiveness.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_c1w4ikxq"
  },
  {
    "question": "Which FeNO value suggests eosinophilic airway inflammation in adult asthma?",
    "options": {
      "A": "<10 ppb",
      "B": "10-25 ppb",
      "C": ">25 ppb",
      "D": ">50 ppb"
    },
    "correctAnswer": "D",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker for type 2 (eosinophilic) airway inflammation. In adults, a FeNO value >50 ppb is strongly suggestive of eosinophilic inflammation and often predicts a good response to inhaled corticosteroids. Values between 25-50 ppb are considered intermediate, while <25 ppb typically indicates low probability of eosinophilic inflammation.",
    "highYieldPearl": "FeNO > 50 ppb strongly suggests eosinophilic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "There are different cut-offs for FeNO depending on the context (e.g., ICS responsiveness, severe asthma). A value of >50 ppb is generally accepted as a high indicator of eosinophilic inflammation in adults.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_g7d4qrf1"
  },
  {
    "question": "What FEV1/FVC ratio is suggestive of airflow limitation in adults for asthma diagnosis?",
    "options": {
      "A": "<0.70",
      "B": "<0.75",
      "C": "<0.80",
      "D": "<0.85"
    },
    "correctAnswer": "A",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Spirometry is essential for asthma diagnosis. A post-bronchodilator FEV1/FVC ratio <0.70 is commonly used to define airflow limitation, particularly in the context of obstructive lung diseases like asthma and COPD. While the lower limit of normal (LLN) is preferred for a more precise diagnosis, the fixed ratio of 0.70 is widely used in clinical practice and for screening.",
    "highYieldPearl": "Post-bronchodilator FEV1/FVC < 0.70 indicates airflow limitation.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Students might confuse the FEV1/FVC ratio with other spirometry parameters or recall the pre-bronchodilator ratio instead of the post-bronchodilator one which is crucial for confirmed airflow limitation in asthma.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_k3464p3n"
  },
  {
    "question": "Which GINA criterion for asthma control involves daytime symptoms more than twice a week?",
    "options": {
      "A": "Well-controlled",
      "B": "Partly controlled",
      "C": "Uncontrolled",
      "D": "Clinically resolved"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "The GINA (Global Initiative for Asthma) guidelines classify asthma control based on a set of criteria over the past 4 weeks. 'Partly controlled' asthma is defined by having one or two of the following: daytime symptoms more than twice a week, any night waking due to asthma, reliever use more than twice a week, or any activity limitation due to asthma.",
    "highYieldPearl": "Daytime symptoms >2x/week = Partly controlled asthma (GINA).",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Misremembering the frequency cut-offs for each control level is a common trap. Students must differentiate between 'twice a week or less' for well-controlled and 'more than twice a week' for partly controlled.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_51tsr82x"
  },
  {
    "question": "Asthma requiring GINA treatment Step 5 or more to remain controlled is classified as?",
    "options": {
      "A": "Moderate persistent",
      "B": "Uncontrolled",
      "C": "Severe",
      "D": "Refractory"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "According to GINA guidelines, 'severe asthma' is defined as asthma that requires Step 4 or 5 treatment to remain controlled, or remains 'uncontrolled' despite this treatment. It is a diagnosis of exclusion, requiring confirmation of adherence, correct inhaler technique, and exclusion of comorbidities.",
    "highYieldPearl": "GINA Step 5 treatment requirement defines severe asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "Students might confuse 'uncontrolled asthma' (a state of control) with 'severe asthma' (a classification based on treatment intensity or persistence of uncontrolled symptoms despite maximal therapy). Severe asthma requires high-level treatment to achieve control or remains uncontrolled despite it.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_yyf0qbk1"
  },
  {
    "question": "What percentage fall in FEV1 post-exercise confirms exercise-induced bronchoconstriction?",
    "options": {
      "A": ">5%",
      "B": ">10%",
      "C": ">15%",
      "D": ">20%"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Exercise-induced bronchoconstriction (EIB) is diagnosed by a significant fall in FEV1 after a standardized exercise challenge. A fall of >10% in FEV1 from baseline, or >12% if an absolute fall of >200 mL is also considered, is generally accepted as diagnostic for EIB. Some guidelines may use >15% for a more definitive diagnosis.",
    "highYieldPearl": "EIB is confirmed by >10% fall in FEV1 post-exercise.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "Similar to bronchodilator reversibility, the exact percentage can vary slightly, but >10% is a widely recognized threshold. Options may include other percentage drops that apply to different diagnostic criteria.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_1e3zeuvi"
  },
  {
    "question": "Which diagnostic test primarily identifies extrinsic triggers in allergic asthma?",
    "options": {
      "A": "FeNO",
      "B": "Sputum eosinophils",
      "C": "Skin prick test",
      "D": "Bronchial challenge test"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Allergic asthma is characterized by an immune response to specific environmental allergens. Skin prick tests (SPT) or specific IgE blood tests are the primary methods to identify these extrinsic triggers. SPT involves introducing small amounts of allergens into the skin and observing for a wheal-and-flare reaction, indicating sensitization.",
    "highYieldPearl": "Skin prick test identifies extrinsic triggers in allergic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Other tests like FeNO and sputum eosinophils indicate inflammation but don't directly identify the specific extrinsic allergen. Bronchial challenge tests confirm hyperresponsiveness, not necessarily the specific trigger.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_w0krroxp"
  },
  {
    "question": "What is the gold standard diagnostic test for Aspirin-Exacerbated Respiratory Disease?",
    "options": {
      "A": "Serum leukotriene levels",
      "B": "Oral aspirin challenge",
      "C": "Nasal provocation test",
      "D": "Bronchial methacholine challenge"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Aspirin-Exacerbated Respiratory Disease (AERD), also known as Samter's Triad, is diagnosed by a history of reactions to aspirin or NSAIDs. The definitive 'gold standard' for diagnosis, especially in equivocal cases, is a carefully conducted, incremental oral aspirin challenge test under medical supervision, observing for respiratory or other systemic reactions.",
    "highYieldPearl": "Oral aspirin challenge is gold standard for AERD diagnosis.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "While nasal provocation tests and elevated leukotriene levels can be suggestive, they are not considered the gold standard. Bronchial methacholine challenge assesses hyperresponsiveness, not aspirin sensitivity.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_giqs2tm4"
  },
  {
    "question": "What percentage of sputum eosinophils is considered significant for eosinophilic asthma phenotype?",
    "options": {
      "A": ">1%",
      "B": ">2%",
      "C": ">3%",
      "D": ">4%"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Sputum eosinophilia is a direct measure of eosinophilic airway inflammation and helps phenotype asthma for targeted therapies. A sputum eosinophil count of >3% (or sometimes >2.5%) of total non-squamous cells is generally considered significant for the eosinophilic asthma phenotype.",
    "highYieldPearl": "Sputum eosinophils >3% indicates eosinophilic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "The exact percentage can vary slightly in literature (e.g., >2.5% or >3%), but >3% is a widely accepted and high-yield cutoff. Lower percentages might be considered abnormal but not necessarily indicative of significant eosinophilic inflammation.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_a1yyv824"
  },
  {
    "question": "What percentage increase in FEV1 and absolute change is diagnostic of asthma reversibility?",
    "options": {
      "A": "10% and 100mL",
      "B": "12% and 200mL",
      "C": "15% and 300mL",
      "D": "20% and 400mL"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Bronchodilator reversibility is a key diagnostic feature of asthma. A significant response is typically defined as an increase in FEV1 of >12% from baseline AND an absolute increase of >200 mL after administration of a short-acting bronchodilator (e.g., 400 mcg salbutamol). This criterion helps differentiate asthma from other obstructive lung diseases like COPD.",
    "highYieldPearl": "Reversibility: >12% and >200mL increase in FEV1 post-bronchodilator.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Students might confuse the percentage with the absolute value, or recall only one of the two criteria. Both must be met for a positive test.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_2u79icch"
  },
  {
    "question": "What is the PC20 threshold for diagnosing bronchial hyperresponsiveness to methacholine?",
    "options": {
      "A": "<1 mg/mL",
      "B": "<4 mg/mL",
      "C": "<8 mg/mL",
      "D": "<16 mg/mL"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "A methacholine challenge test assesses bronchial hyperresponsiveness (BHR), a hallmark of asthma. A positive test is defined as a fall in FEV1 of 20% or more from baseline (PC20) at a methacholine concentration of 8 mg/mL or less. While some guidelines may consider up to 16 mg/mL, <8 mg/mL is a more definitive and commonly accepted threshold for clinical significance.",
    "highYieldPearl": "Methacholine PC20 < 8 mg/mL indicates bronchial hyperresponsiveness.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "The exact PC20 value can vary slightly between guidelines, but <8 mg/mL is the most common and robust answer. Distracting options might include higher values which indicate less hyperresponsiveness.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_qwzu7uqf"
  },
  {
    "question": "Which FeNO value suggests eosinophilic airway inflammation in adult asthma?",
    "options": {
      "A": "<10 ppb",
      "B": "10-25 ppb",
      "C": ">25 ppb",
      "D": ">50 ppb"
    },
    "correctAnswer": "D",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker for type 2 (eosinophilic) airway inflammation. In adults, a FeNO value >50 ppb is strongly suggestive of eosinophilic inflammation and often predicts a good response to inhaled corticosteroids. Values between 25-50 ppb are considered intermediate, while <25 ppb typically indicates low probability of eosinophilic inflammation.",
    "highYieldPearl": "FeNO > 50 ppb strongly suggests eosinophilic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "There are different cut-offs for FeNO depending on the context (e.g., ICS responsiveness, severe asthma). A value of >50 ppb is generally accepted as a high indicator of eosinophilic inflammation in adults.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_013lxx4b"
  },
  {
    "question": "What FEV1/FVC ratio is suggestive of airflow limitation in adults for asthma diagnosis?",
    "options": {
      "A": "<0.70",
      "B": "<0.75",
      "C": "<0.80",
      "D": "<0.85"
    },
    "correctAnswer": "A",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Spirometry is essential for asthma diagnosis. A post-bronchodilator FEV1/FVC ratio <0.70 is commonly used to define airflow limitation, particularly in the context of obstructive lung diseases like asthma and COPD. While the lower limit of normal (LLN) is preferred for a more precise diagnosis, the fixed ratio of 0.70 is widely used in clinical practice and for screening.",
    "highYieldPearl": "Post-bronchodilator FEV1/FVC < 0.70 indicates airflow limitation.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Students might confuse the FEV1/FVC ratio with other spirometry parameters or recall the pre-bronchodilator ratio instead of the post-bronchodilator one which is crucial for confirmed airflow limitation in asthma.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_cxk5p8aq"
  },
  {
    "question": "Which GINA criterion for asthma control involves daytime symptoms more than twice a week?",
    "options": {
      "A": "Well-controlled",
      "B": "Partly controlled",
      "C": "Uncontrolled",
      "D": "Clinically resolved"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "The GINA (Global Initiative for Asthma) guidelines classify asthma control based on a set of criteria over the past 4 weeks. 'Partly controlled' asthma is defined by having one or two of the following: daytime symptoms more than twice a week, any night waking due to asthma, reliever use more than twice a week, or any activity limitation due to asthma.",
    "highYieldPearl": "Daytime symptoms >2x/week = Partly controlled asthma (GINA).",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Misremembering the frequency cut-offs for each control level is a common trap. Students must differentiate between 'twice a week or less' for well-controlled and 'more than twice a week' for partly controlled.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_ixn3y51k"
  },
  {
    "question": "Asthma requiring GINA treatment Step 5 or more to remain controlled is classified as?",
    "options": {
      "A": "Moderate persistent",
      "B": "Uncontrolled",
      "C": "Severe",
      "D": "Refractory"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "According to GINA guidelines, 'severe asthma' is defined as asthma that requires Step 4 or 5 treatment to remain controlled, or remains 'uncontrolled' despite this treatment. It is a diagnosis of exclusion, requiring confirmation of adherence, correct inhaler technique, and exclusion of comorbidities.",
    "highYieldPearl": "GINA Step 5 treatment requirement defines severe asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "Students might confuse 'uncontrolled asthma' (a state of control) with 'severe asthma' (a classification based on treatment intensity or persistence of uncontrolled symptoms despite maximal therapy). Severe asthma requires high-level treatment to achieve control or remains uncontrolled despite it.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_2qvjhp73"
  },
  {
    "question": "What percentage fall in FEV1 post-exercise confirms exercise-induced bronchoconstriction?",
    "options": {
      "A": ">5%",
      "B": ">10%",
      "C": ">15%",
      "D": ">20%"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Exercise-induced bronchoconstriction (EIB) is diagnosed by a significant fall in FEV1 after a standardized exercise challenge. A fall of >10% in FEV1 from baseline, or >12% if an absolute fall of >200 mL is also considered, is generally accepted as diagnostic for EIB. Some guidelines may use >15% for a more definitive diagnosis.",
    "highYieldPearl": "EIB is confirmed by >10% fall in FEV1 post-exercise.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "Similar to bronchodilator reversibility, the exact percentage can vary slightly, but >10% is a widely recognized threshold. Options may include other percentage drops that apply to different diagnostic criteria.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_3cji3nn6"
  },
  {
    "question": "Which diagnostic test primarily identifies extrinsic triggers in allergic asthma?",
    "options": {
      "A": "FeNO",
      "B": "Sputum eosinophils",
      "C": "Skin prick test",
      "D": "Bronchial challenge test"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Allergic asthma is characterized by an immune response to specific environmental allergens. Skin prick tests (SPT) or specific IgE blood tests are the primary methods to identify these extrinsic triggers. SPT involves introducing small amounts of allergens into the skin and observing for a wheal-and-flare reaction, indicating sensitization.",
    "highYieldPearl": "Skin prick test identifies extrinsic triggers in allergic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Easy",
    "trapAnalysis": "Other tests like FeNO and sputum eosinophils indicate inflammation but don't directly identify the specific extrinsic allergen. Bronchial challenge tests confirm hyperresponsiveness, not necessarily the specific trigger.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_pt0lwsgp"
  },
  {
    "question": "What is the gold standard diagnostic test for Aspirin-Exacerbated Respiratory Disease?",
    "options": {
      "A": "Serum leukotriene levels",
      "B": "Oral aspirin challenge",
      "C": "Nasal provocation test",
      "D": "Bronchial methacholine challenge"
    },
    "correctAnswer": "B",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Aspirin-Exacerbated Respiratory Disease (AERD), also known as Samter's Triad, is diagnosed by a history of reactions to aspirin or NSAIDs. The definitive 'gold standard' for diagnosis, especially in equivocal cases, is a carefully conducted, incremental oral aspirin challenge test under medical supervision, observing for respiratory or other systemic reactions.",
    "highYieldPearl": "Oral aspirin challenge is gold standard for AERD diagnosis.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "While nasal provocation tests and elevated leukotriene levels can be suggestive, they are not considered the gold standard. Bronchial methacholine challenge assesses hyperresponsiveness, not aspirin sensitivity.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_gy5718vu"
  },
  {
    "question": "What percentage of sputum eosinophils is considered significant for eosinophilic asthma phenotype?",
    "options": {
      "A": ">1%",
      "B": ">2%",
      "C": ">3%",
      "D": ">4%"
    },
    "correctAnswer": "C",
    "topic": "asthma_diagnosis",
    "deepDiveExplanation": "Sputum eosinophilia is a direct measure of eosinophilic airway inflammation and helps phenotype asthma for targeted therapies. A sputum eosinophil count of >3% (or sometimes >2.5%) of total non-squamous cells is generally considered significant for the eosinophilic asthma phenotype.",
    "highYieldPearl": "Sputum eosinophils >3% indicates eosinophilic asthma.",
    "examStyle": "NEET-SS",
    "difficulty": "Medium",
    "trapAnalysis": "The exact percentage can vary slightly in literature (e.g., >2.5% or >3%), but >3% is a widely accepted and high-yield cutoff. Lower percentages might be considered abnormal but not necessarily indicative of significant eosinophilic inflammation.",
    "isOneLiner": true,
    "id": "one_liner_asthma_diagnosis_fg44eyna"
  }
]